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SUMMARY 
Obesity is increasing in prevalence, in both the developed and the developing worlds 
This is due to an increase in the availability of energy dense food and globally 
reduced levels of physical activity. Obesity would appear to be the driving force for 
increased prevalence of type 2 diabetes.  
 
The processes that lead to the development of insulin resistance and ultimately type 
2 diabetes may also play a significant role in the development of endothelial function. 
Biological changes leading to insulin resistance may also cause impairment of 
endothelium-mediated vasodilatation. This is thought to be one of the first 
manifestations of atherosclerotic cardiovascular disease (CVD), also a major burden 
on individuals and health services. Endothelial dysfunction has been shown to be a 
surrogate marker of underlying risk for atherosclerotic cardiovascular disease. 
 
The effects of intentional weight loss on reducing the burden of cardiovascular 
disease remain unclear. Although it is recognised that intentional weight reduction 
can ameliorate insulin resistance, hypertension and abnormalities of lipoprotein 
metabolism, there is little evidence to suggest that weight loss reduces CVD-related 
morbidity. A number of studies have attempted to address this issue by assessing 
the effects of weight loss on endothelial function. However, few of these studies have 
included subjects with type 2 diabetes, and a number of them have included exercise 
interventions, which have been shown to have effects on vasculature over and 
above the effects of weight reduction. 
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Given the increased risk of cardiovascular morbidity and mortality associated with 
type 2 diabetes, and the need for further strategies addressing this issue, this study 
aimed to assess the effects of intentional weight loss using solely dietary 
manipulation in a cohort of subjects with type 2 diabetes.  
 
Fifteen male and female subjects with type 2 diabetes were recruited from local 
diabetes clinics and advertisements in local press. A six-week period of dietary 
intervention in the form of a 1200kal/day liquid diet was prescribed, with subjects 
being closely monitored by a dietician during this period. Vascular and metabolic 
assessments were performed at baseline and following a one-week dietary washout 
period at the end of the intervention. 
 
This dietary intervention led to significant reductions in body weight, waist and hip 
circumferences and body fat percentage, measured by three distinct methods. 
Change in body weight correlated with change in waist circumference, but there 
were no correlations between change in body composition or any of the other 
anthropometric measurements. The probable reason for this was the small numbers 
involved. 
 
Weight reduction was associated with improvements in metabolic parameters. 
Significant reductions in fasting plasma glucose, glycated haemoglobin and whole 
body insulin sensitivity as measured by the isoglycaemic hyperinsulinaemic clamp 
technique were noted after the intervention. In addition, there were significant 
reductions in liver enzymes (surrogate markers of hepatic steatosis), and in serum 
 28 
total cholesterol concentrations. Changes in glycaemic control were closely 
correlated with changes in liver enzymes. 
 
With the exception of serum intercellular adhesion molecule-1 (ICAM-1), there were 
no improvements in any of the measured concentrations of adipocytokines or 
inflammatory markers following weight reduction. Serum concentrations of ICAM-1 
were significantly reduced as a result of the intervention, with no changes in C-
reactive protein, interleukin-6 or adiponectin being observed. The possible reasons 
for these results are multifactorial.  
 
Weight loss was associated with variable effects on vascular function. Three 
modalities were employed for the assessment of the vasculature; wire myography, 
laser Doppler inontophoresis and pulse wave analysis / velocity measurements. 
Significant reductions in endothelium-dependent vasodilatation as measured by both 
wire myography and laser Doppler iontophoresis were observed after weight 
reduction. In contrast, however, there was a significant improvement in pulse wave 
velocity measurements.  
 
In summary, weight reduction in a cohort of subjects with type 2 diabetes led to 
significant improvements in metabolic parameters, little change in markers of 
inflammation and a deterioration in endothelium-dependent vasodilatation. 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.0 Introduction  
Obesity, defined as a body mass index (BMI) of > 30kg/m2 is increasing in 
prevalence, in both the developed and the developing worlds. This is most probably 
due to an increase in the availability of energy dense, inexpensive food that is of low 
nutritional quality and high in fat and globally reduced levels of physical activity. 
Obesity would appear to be the driving force for increased levels of type 2 diabetes 
(Gregg at al, 2004), the prevalence of which for all age groups worldwide was 
estimated to be 2.8% in 2000 and is predicted to rise to 4.4% in 2030. The total 
number of people with diabetes is projected to rise from 171 million in 2000 to 366 
million in 2030 (Wild et al, 2004). 
 
Biological changes leading to insulin resistance may also play a role in the 
development of endothelial dysfunction, which is thought to be one of the first 
manifestations of atherosclerotic cardiovascular disease (CVD), also a major burden 
on individuals and health services. The effects of intentional weight loss on reducing 
this burden remain unclear. 
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1.1 Epidemiology of obesity 
1.1.1 Obesity in Europe and the USA 
Data on the prevalence of obesity in the USA comes from two sources; the 
Behavioural Risk Factor Surveillance System (BRFSS) and the National Health and 
Nutrition Examination Survey (NHANES). The BRFSS conducts annual telephone 
surveys of randomly selected individuals who are representative of the general 
population, and subjects are asked to self-report on height and weight. The NHANES 
population have height and weight measured by a health professional: the latest 
survey suggested a prevalence of BMI of >30kg/m2 of 32.2% in North American 
adults over the age of 20 years (Ogden et al 2006). Self-reported BRFSS data 
suggest a figure about 8% lower than the NHANES data. 
 
In Europe, the most reliable estimates of obesity prevalence come from the UK. The 
Health Surveys for England database examines long-term trends in body weight and 
other demographic variables.  In the most recent survey from 2003, it was estimated 
that 22% of men and 23% women were overweight. A further report from this 
organisation has estimated that if current trends continue, a further 3.5 million people 
in the UK will be obese by 2010 (Health Survey for England / DOH). 
 
 
 1.1.2 Obesity in the Developing World 
The prevalence of non-communicable diseases is increasing at an alarming rate in 
the developing world, with worldwide figures of 18 million deaths per year from CVD 
in 2004. Projected figures suggest that this will increase to around 24 million by 
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2030. It has been estimated that cardiovascular mortality rates will increase further in 
low and medium income countries than in high-income countries (The global burden 
of disease report update: 2004 update; WHO publications). The main driving force 
for this significant increase in CVD mortality is the global pandemic of type 2 
diabetes, which is associated with increased rates of obesity. The estimate of 
worldwide obesity currently stands at 312 billion (Hossain et al, 2007).  
 
Rates of obesity in developing countries have tripled over the past 20 years as a 
result of reduced energy expenditure and the consumption of inexpensive energy-
dense food. People from the Middle East, Pacific Islands, Southeast Asia and China 
seem to be at greatest risk of obesity and its complications (Hossain et al, 2007). 
These developing countries in particular face the paradox of families in which the 
children are underweight and the adults are overweight (Hossain et al, 2007). This 
combination has been attributed to intrauterine growth retardation and resulting low 
birth weight, which apparently confer a predisposition to obesity later in life through a 
"thrifty" phenotype that, when accompanied by rapid childhood weight gain, is 
conducive to the development of insulin resistance and the metabolic syndrome 
(Hales et al 1992, Diabetologia). 
 
 
 1.1.3 Risk factors for obesity 
Several epidemiological studies have shown that certain demographic, sociocultural 
and behavioural factors are associated with overweight and obesity. For example, 
the Health Survey for England illustrates associations between increasing age, 
 32 
female gender and obesity. Obesity and overweight also seem to be associated with 
lower socio-economic status in industrial societies, although this relationship may not 
be so striking in the developing world, where middle income individuals seem to be 
at higher risk of obesity. The long-term effects of lifestyle in adults have been more 
difficult to assess. However, one retrospective questionnaire-based study has 
suggested some lifestyle factors that are associated with obesity in older adults. 
Data was analysed from the National Health Interview Survey, which is distributed to 
40,000 households across all states in the US. In males aged older than 50 years, 
obesity was associated with previous smoking history, eating less than two portions 
of fruit / vegetables per day, and light to moderate alcohol intake. Obese males were 
less likely to walk for leisure or transportation purposes than overweight or normal 
weight males. Risk factors were noted to be similar for older females, with the 
exception that women who drank no alcohol were more likely to be overweight than 
those with light or moderate alcohol consumption (Kruger et al, 2009). 
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1.2 MEASURES OF BODY COMPOSITION 
1.2.1 Anthropometric measures of body composition 
a. Body mass index 
Body mass index (BMI) is the most commonly used parameter of underweight or 
obesity, and is calculated by dividing body weight (in kilograms) by the square of 
height (in metres). This measurement is commonly used both in clinical practice and 
in the clinical trial setting. BMI is a useful tool for observing secular trends and 
regional variations in countries. In population settings there is good correlation 
between BMI and percentage body fat. The measurement has formed the basis for 
worldwide classifications of obesity, with a BMI of 20-24.9 kg/m2 being classed as 
normal, with the “ideal” suggested as 23 kg/m2. „Overweight‟ (grade 1 obesity) is 
defined as 25-29.9 kg/m2, obesity (grade 2) as BMI 30-39.9 kg/m2, and morbid 
obesity (grade 3) as >40 kg/m2 (World Health Organization, 1995). 
 
Associations between BMI and mortality have been repeatedly demonstrated in 
studies (Engeland A et al. 2003; Zhu S et al 2003). These studies have 
demonstrated that the relationship between BMI and all-cause mortality is U or J 
shaped – mortality is lowest at approximately 23 kg/m2 and increases both with 
increasing obesity and under-nourished states. BMI is therefore useful in population 
assessments to document trends in obesity, or to assess health inequalities between 
populations.  
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However, BMI is relatively less useful in the practice of obesity management. Its 
main drawback is that it gives no estimate of body composition or excess fat mass. It 
may therefore overestimate body fat in certain clinical scenarios such as reduced 
height due to kyphosis, or increased body weight due to oedema or increased 
muscularity.  
 
Ageing leads to a progressive increase in the ratio between fat and lean body mass, 
and this trend has been shown in subjects whose BMI remains constant throughout 
life, suggesting that BMI cannot be a true indication of body fat mass throughout life. 
A number of differences in the relationship between BMI and body fat between 
ethnic groups have also been demonstrated. Asians have been shown to have a 
higher percentage of body fat for a given BMI (WHO Expert Consultation, 2004), 
while the reverse is true for African-Americans (Banerji et al, 1999; Deurenberg et al, 
1995). In addition, certain groups in society such as athletes and military and civil 
forces personnel are often considerably leaner than suggested by their BMI. 
 
b. Skinfold thickness 
The measurement of skinfold thickness at a number of body sites to estimate body 
fat stores has been employed for many years. Subcutaneous fat is measured using 
callipers that exert a standard pressure, and from these measurements body density 
can be predicted. Percentage body fat can then be estimated using either the Bro
ek (1963) or Siri (1961) equation. Skinfold thickness is commonly measured at four 
sites: triceps, biceps, subscapular and suprailiac. After log transformation of the 
data, there is a linear relationship between the sum of the skinfold thickness at these 
sites and body density, which is age and gender specific (Durnin et al 1973, 1974).  
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Fuller et al (1992) have shown that measurements made by a single observer can 
give good agreement with reference methods. However the technique contains the 
error associated with the prediction of body density. Although the density of fat mass 
is reasonably constant, that for the fat-free mass is variable, due to inter-individual 
differences in bone mineral mass and total body water. In addition the technique has 
been shown to be poorly reproducible between observers (Fuller et al 1991). There 
may also be specific problems in the obese including the compressibility of large 
subcutaneous fat pads, and the presence of oedema. 
 
 
1.2.2 Other methods of assessing body composition 
A number of methods of measuring body composition have been developed over the 
past few decades. These methods are described as two, three, or four compartment 
models, depending on the amount of information they provide on the different 
components of the body‟s lean or “fat free” mass (FFM). 
 
a. Two compartment models 
Development of the classic two compartment (2-C) model of body composition has 
accelerated in recent years because of the association of excess body fat with 
increased risk for cardiovascular disease. In the basic 2-C model, the body is divided 
into two parts: body fat and fat free mass (FFM). There are a number of methods of 
measuring body composition based on this model. 
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Underwater weighing 
Underwater weighing was the first 2-C model of body composition to be used, and 
remains the gold standard for measuring body composition. This method involves 
fully submerging the subject in water; the volume of water being displaced and the 
subject‟s body weight are used to calculate the body density (Db). Studies have 
shown that the density of fat is relatively constant in humans. However, because of 
its heterogeneous nature, the density of fat-free mass varies depending on the 
amount of water (Forslund et al 1996) or bone mineral (Martin and Drinkwater 1991) 
it contains. Therefore, there is a degree of error associated with this method in 
estimating body fat percentage. In addition it is an impractical and cumbersome 
procedure to perform or undergo. 
 
Air displacement plethysmography 
Air displacement plethysmography (ADP) has been in use since the early 1900‟s but 
has only recently started to replace underwater weighing as a means of measuring 
body composition. The subject is not immersed in water, but in a closed air-filled 
chamber. The system consists of two chambers: one for the subject and the other 
serving as a reference volume. The volume of an object is measured indirectly by 
measuring the volume of air it displaces within a closed chamber. Body volume is 
calculated indirectly by subtracting the volume of air remaining inside the chamber 
when the subject is inside, from the volume of air in the chamber when it is empty. 
The air inside the chamber is measured by applying relevant physical gas laws. 
Boyle‟s Law states that at a constant temperature, volume (V) and pressure (P) are 
inversely related: 
    P1 / P2  = V1 / V2   
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However, the requirement for constant temperatures within these systems previously 
made measurements arduous and impractical. Difficulties in maintaining isothermal 
conditions arose as a result of rapid fluctuations in temperature, humidity and 
pressure generated by humans entering the enclosed chamber (Friis Hansen et al, 
1963; Gundlach et al, 1986).  
   
In the mid 1990‟s the BOD POD became the first commercially available air-
displacement plethysmograph. The design and operating principles of this system 
are described in detail elsewhere (Dempster 1995; Life Measurement, Inc. BOD 
POD body composition system: operator's manual. Concord, CA: Life Measurement, 
Inc, 1997).  With this system, it is unnecessary to conduct measurements under 
isothermal conditions, the air being allowed to compress and expand adiabatically 
(i.e. freely gaining and losing heat during compression and expansion). The BOD 
POD makes use of Poisson‟s law, which describes the pressure-volume relationship 
under adiabatic conditions: 
  P1 / P2  =  (V1 / V2 )
γ   
where γ is the ratio of the specific heat of the gas at constant pressure to that of 
constant volume and is equal to 1.4 for air. Body density and body fat can then be 
estimated by a variety of calculations. 
 
The BOD POD has been shown in a number of studies to be reliable in assessing 
both body volume and body fat percentage (Sardinha et al, 1998; Biaggi et al, 1999) 
and shows excellent comparison with UWW, with improved reproducibility and 
enhanced subject acceptability (Fields et al, 2002). Although this method presents 
similar problems to UWW with respect to the heterogeneous nature of the fat-free 
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mass, it is a useful method in assessing changes in body composition after a period 
of weight loss. 
 
b. Three compartment models 
The theory behind three compartment (3-C) models of body composition is that fat-
free mass is divided into two components: its water content and the remaining solids 
(predominantly proteins and minerals). Three compartment models tend to be based 
on dilution techniques measuring total body water, in combination with a classical 2-
C measure of body density. The basic principle behind these methods is that the 
volume of a compartment can be defined as the ratio of the dose of a tracer to its 
concentration in that body compartment within a short time after the dose is 
administered. 
 
The most commonly used method is the estimation of total body water (TBW). This 
is measured using a tracer dose of labelled water (deuterium, tritium or oxygen-18) 
and collection of body fluid samples pre and post ingestion. The estimated error for a 
TBW is typically <1kg, which translates to an error of roughly 10% for the average 
man for absolute fat mass.    
 
Alternative dilutional methods for estimation of body composition include 
measurements of extracellular and intracellular water. 
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c. Four compartment models 
The development of dual energy X-ray absorptiometry (DXA) to measure whole body 
bone mineral content has led to increasing accuracy in the measurement of body 
composition. Four-compartment models combine measurements of BMD with total 
body water, and allow calculation of the true density of fat-free mass. This is 
probably the most accurate way to date of assessing body composition (Fuller et al 
1992), but has not yet been widely applied because of certain practical issues, 
especially in obese individuals. Subjects often exceed the weight capacity of 
machines, and the scanning area is relatively small and usually inadequate for most 
obese people. 
 
 
1.2.3 Measuring body fat distribution 
In addition to body weight, body fat distribution is also an important risk factor for 
obesity related diseases. Excess abdominal or central fat is associated with an 
increased risk of cardiometabolic disease such as type 2 diabetes (Ohlson et al, 
1985). 
 
a. Waist circumference 
Waist circumference (WC) is often used as a surrogate marker of abdominal fat 
mass, as it correlates well with both subcutaneous and intra-abdominal fat as 
measured by CT scanning and MRI scanning respectively (Pouliot at al, 1994; Chan 
et al, 2003), and is associated with cardiometabolic risk (Kissebah et al, 1982). Men 
and women who have waist circumferences greater than 102cm and 94cm 
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respectively are considered to be at increased risk of cardiometabolic disease (Wang 
et al, 2005). The World Health Organisation has adopted these cut-off points, 
although some are of the opinion that these are rather arbitrary (Stevens et al, 2001).  
 
Waist circumference is closely associated with BMI, and both BMI and WC correlate 
strongly with total body adipose tissue, but there is evidence to suggest that WC is a 
stronger predictor of intra-abdominal adipose tissue than is BMI (Shen et al, 2004). 
 
There is consistent evidence that WC is strongly correlated with the development of 
type 2 diabetes (Carey et al, 1997; Chan et al, 1994; Ohlson et al, 1985), and that it 
is a stronger predictor than BMI (Wei et al; 1997). Some investigators have 
suggested that increasing waist circumference is an independent risk factor for CHD 
and mortality, even after correction for other “traditional” risk factors such as 
hypercholesterolaemia (Dagenais et al, 2005).  
 
b. Waist Hip Ratio 
Waist hip ratio has been routinely used as a clinical and research tool in the 
measurement of abdominal obesity. This measurement correlates well with BMI, but 
it has been demonstrated that a simple measurement of waist circumference is a 
better correlate of visceral adipose tissue accumulation (Pouliot et al, 1999; Onat et 
al, 2004; Kamel et al, 1999). However, because of the negative correlation of hip 
circumference with traditional risk factors, there is evidence to suggest that WHR is a 
better predictor of cardiovascular events (de Koning et al 2007). 
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c. Computerised Tomography (CT) and Magnetic Resonance Imaging (MRI) 
Imaging techniques such as MRI and CT scanning have taken an anatomical 
approach to body composition analysis. It is possible using both of these techniques 
to measure total body composition by interpolating multiple slices. However, this is 
impractical because of limited availability of resources and time for reporting, and the 
amount of exposure to radiation in the case of CT. Both of these techniques, 
however, can be used to measure body composition at specific sites, usually intra-
abdominal fat. The other benefit of this is that subcutaneous fat can be differentiated 
from visceral fat. There is also evidence of good correlation between fat mass 
measured in a single CT slice measured at L4 to L5 and total visceral fat volume 
(Kvist et al 1986), thus reducing time and radiation exposure to the subject. 
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1.3 Obesity and insulin resistance  
1.3.1 Insulin and the insulin receptor 
Insulin consists of two linked polypeptide chains and is secreted by the beta cells of 
the pancreas in response to glucose and amino acids. Insulin is a potent anabolic 
hormone and promotes the synthesis and storage of carbohydrates, lipids and 
proteins while inhibiting their degradation and release back into the circulation. The 
major sites of insulin action are skeletal muscle and adipocytes, although it is now 
recognised that insulin receptors are present in many other tissues, including beta 
cells of the pancreas and the vascular endothelium. The cellular actions of insulin 
are mediated by the membrane-located insulin receptor. 
 
The insulin receptor is a heterotetramer that consists of two alpha-beta dimers made 
up by 3 disulphide bonds. Tyrosine kinase catalyses the phosphorylation of several 
intracellular substrates, including the insulin receptor substrate (IRS) proteins, each 
of which recruits a distinct set of signalling proteins. To date, most attention has 
focussed on the IRS family of proteins, although it is also thought that the mitogen-
activated protein (MAP) kinase plays an important role in insulin signalling. Mice 
lacking the IRS-1 protein are insulin resistant but not overtly diabetic (Tamemoto et 
al, 1994), and mice lacking the IRS-2 protein exhibit diabetes (Withers et al, 1998). 
 
The insulin receptor catalyses the tyrosine phosphorylation of the IRS-family 
proteins, which generates docking sites for several SH2-containing proteins, 
including the p85 regulatory subunit of the type 1A phosphatidylinositol (PtdIns) 3-
kinase (PI3-K). This ultimately results in translocation of a glucose transport protein, 
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GLUT4, to the cell membrane via a process of targeted exocytosis. GLUT4 
endocytosis is simultaneously attenuated. The combination of translocation and 
reduction of endocytosis results in an accumulation of plasma-membrane-localised 
GLUT4, which allows inflow of glucose into the cell. 
 
 
1.3.2 Measuring insulin resistance 
Techniques for measuring insulin sensitivity in vivo are of varying complexity and 
range from simple fasting plasma insulin to the direct, but more time-consuming and 
labour-intensive, “gold standard” euglycaemic hyperinsulinaemic clamp. Advantages 
and disadvantages of these methods are outlined below. 
 
Euglycaemic hyperinsulinaemic clamp (DeFronzo et al, 1979); A primed then 
constant exogenous insulin infusion maintains a steady state high physiological 
hyperinsulinaemia while suppressing endogenous β cell insulin secretion and hepatic 
glucose production. Glucose is infused at a variable rate in order to maintain blood 
glucose at a predetermined level (measured every five minutes at the bedside).  At 
steady state the glucose infusion rate is equal to the rate of glucose uptake into 
tissues, i.e. insulin sensitivity, the assumption being made that hepatic glucose 
output is completely suppressed. Initial clamp studies used arterial blood samples for 
analysis of serum glucose levels, but hand warming is now widely used to 
“arterialise” venous blood (Petrie et al, 1996). Reproducibility is better when a three-
hour rather than two hour clamp is performed (Morris et al, 1997).  
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Insulin suppression test; Glucose and insulin infusion rates are held constant, with 
steady state being achieved once plasma glucose reaches a plateau. Endogenous 
insulin release is suppressed using somatostatin. Steady state plasma glucose is 
used as an index of insulin sensitivity.   
 
Frequently sampled intravenous glucose tolerance test with minimal model analysis; 
This technique, in which up to 22 glucose samples are obtained for the mathematical 
calculation of insulin sensitivity, has been reported as having a high degree of 
correlation with values of insulin sensitivity generated using the euglycaemic 
hyperinsulinaemic clamp in healthy volunteers (Anderson et al, 1995). In subjects 
with type 2 diabetes, however, the correlation is less strong, particularly when the 
number of glucose samples is reduced to twelve. As such, this technique is best 
employed in studies of non-diabetic populations. 
 
Short insulin tolerance test; This is based on the rate at which plasma glucose falls 
during the first twenty minutes following an intravenous bolus of insulin. 
 
Plasma insulin; Fasting plasma insulin has been used as a surrogate measure of 
insulin resistance, based on the assumption that compensatory hyperinsulinaemia 
occurs under normal circumstances in proportion to the degree of insulin resistance. 
The main difficulties in interpreting these values are variations in the performance of 
even the same assay kit across centres and possibly differences in specificity of 
insulin vs. its precursor molecules (Nagi et al, 1990; Petrie et al, 1997; Cotes et al, 
1969). 
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Post-load insulin; Plasma insulin, sampled one or two hours after a glucose load, has 
been used in some prospective studies of hyperinsulinaemia and cardiovascular 
disease, such as the Busselton (Welborn et al, 1979) and Paris (Ducimetiere et al, 
1980) cohorts. 
 
Homeostasis Model Assessment (HOMA) and Fasting Insulin Resistance Index 
(FIRI); These simple indices are derived from fasting insulin and glucose levels. In 
non-diabetic populations, positive correlation with fasting insulin is almost unity. 
However, in datasets from which diabetic subjects have not formally been excluded, 
HOMA may provide a better surrogate measurement of insulin sensitivity than fasting 
insulin (Petrie et al, 1997). 
 
 
1.3.3 Free fatty acids and insulin resistance 
Associations between insulin resistance and obesity were noted as far back as 1965 
(Randle et al 1965). Circulating concentrations of free fatty acid (FFA) are elevated 
in obesity because of increased production and reduced clearance of FFAs. In 
addition, elevated plasma FFA concentrations inhibit the anti-lipolytic action of 
insulin, further increasing the rate of FFA release into the circulation. .  
 
In skeletal muscle, acute elevations in plasma FFA concentrations (by infusing 
heparinized lipid emulsions) reduces insulin-stimulated glucose uptake in individuals 
irrespective of gender and age (Roden et al, 1996). Under these conditions, insulin 
resistance develops 2–4 hours after elevation of plasma FFA concentrations and 
disappears 4 hours after normalization of FFA concentrations. 
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 FFA-induced hepatic insulin resistance is more difficult to demonstrate because the 
liver is more insulin sensitive than skeletal muscle. Nevertheless, there is convincing 
evidence that physiological elevations of FFA, such as seen after a fat rich meal, 
inhibit insulin suppression of hepatic glucose production (HGP) resulting in an 
increase in HGP (Boden et al, 1997). In the acute setting, this rise in HGP is due to 
FFA-mediated inhibition of insulin suppression of glycogenolysis (Boden et al, 2002). 
 
Chronically elevated plasma FFA concentration, are also associated with insulin 
resistance, and it has been demonstrated that short-term reduction of elevated 
plasma FFA concentrations improves insulin sensitivity. Normalization of plasma 
FFA concentrations resulted in significant improvements in insulin-stimulated 
glucose uptake in obese non-diabetic individuals and in patients with T2DM 
(Santomauro et al, 1999). Similar results have been reported in non-diabetic subjects 
genetically predisposed to T2DM (Cusi et al, 2007). 
 
 
 
Further work has demonstrated the link between lipid accumulation in hepatic and 
skeletal muscle tissue, and the pathogenesis of insulin resistance (Savage et al 
2007).The investigations of Savage et al demonstrated that infusion of lipids into the 
plasma led to significant accumulation of intracellular lipids especially diacylglycerol 
and fatty acyl-CoA in liver and muscle tissue. They revealed a negative correlation 
between intracellular lipids and rates of muscle glycogen synthesis and glucose 
oxidation i.e. insulin resistance in healthy human subjects, using the technique of 
nuclear magnetic resonance spectroscopy. Savage et al also demonstrated that 
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intracellular lipids inhibited the glucose transporter, GLUT4, the rate-limiting step in 
glycogen synthesis and glucose transport in skeletal muscle. 
 
Choi et al (2007) subsequently investigated the molecular mechanisms whereby 
accumulation of lipid in liver and muscle would cause insulin resistance. Increased 
intracellular diacylglycerol (DAG) activates protein kinase C, and this initiates a 
serine / threonine phosphorylation cascade that phosphorylates insulin receptor 
substrate-1 (IRS-1). This inhibits tyrosine phosphorylation of IRS-1 and downstream 
activation of PI3 kinase, leading to reduced activation of v-akt murine thymoma viral 
oncogene homolog 2 (Akt2). This in turn affects translocation of GLUT4 and reduced 
glucose transport into cells.  
 
 
 
1.3.4 Insulin resistance and adipocytokines 
Proteins or “adipocytokines” secreted by adipose tissue appear to play an active role 
in metabolism including the modification of insulin sensitivity. The most important of 
these factors are described below.  
 
a. Tumour necrosis factor alpha 
Tumour necrosis factor- (TNF-) is an inflammatory cytokine, which until recently 
was thought to be produced mainly by macrophages.  Hotamisligil et al, (1993) 
demonstrated increased levels in the adipose tissue of obese rodents, hypothesising 
that TNF is also secreted by white adipose tissue. Subsequent works have 
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revealed similar findings in humans and TNF levels correlate well with obesity and 
insulin resistance (Hotamisligil et al 1995; Kern at al 1995). Some data has also 
suggested that circulating concentrations of TNF are increased in subjects with 
obesity or impaired glucose tolerance. 
 
Whilst these studies suggest an association between TNF and obesity, studies 
showing improved insulin sensitivity in rodent models of obesity with neutralisation of 
TNF, have been central to the hypothesis that this molecule plays an active role in 
insulin resistance (Hotamisiligil et al 1993; Cheung et al 1998). There are a number 
of hypothesized mechanisms that could potentially explain the effects of TNF on 
insulin resistance. Firstly, TNF increases lipolysis, thus increasing circulating free 
fatty acid concentrations that affect insulin sensitivity. In addition, it has been 
demonstrated in vitro that high levels of TNFα can inhibit GLUT4 synthesis, thereby 
reducing insulin-mediated glucose transport (Stephens et al, 1996). Finally, TNFα is 
thought to have deleterious effects on insulin signalling by promoting serine 
phosphorylation of IRS-1 (Hotamisligil et al 2006). 
 
 
b. Interleukin-6 
Interleukin-6 (IL-6) is one of the mediators of the acute phase response and is 
secreted by many cell types, including adipocytes. Studies have shown that plasma 
IL-6 concentrations are elevated in obesity and the metabolic syndrome (Kern et al, 
2001), and elevated plasma levels of IL-6 are predictive of the development of type 2 
diabetes (Pradhan et al, 2001) and future myocardial infarction (Ridker et al, 2000). 
 49 
Serum and adipose tissue levels of IL-6 are reduced by weight loss (Bastard et al, 
2000), leading to the conclusion that IL-6 may contribute to insulin resistance in 
obesity. 
 
c. Adiponectin 
Adiponectin is made exclusively by adipocytes and was first reported in 1995. Unlike 
other adipocytokines, adiponectin mRNA is reduced in adipose tissue from obese 
mice and humans. Serum adiponectin levels correlate negatively with obesity (Arita 
et al, 1999), central obesity and insulin resistance (Weyer et al, 2001). In case-
control studies, low plasma adiponectin has been shown to be an independent risk 
factor for future development of type 2 diabetes (Lindsay et al, 2002; Spranger et al, 
2003) 
 
Administration of adiponectin has been shown to reverse insulin resistance in rodent 
models of type 2 diabetes and obesity (Yamauchi et al, 2003). Adiponectin may 
ameliorate insulin resistance by decreasing circulating FFA by increasing fatty acid 
oxidation by skeletal muscle (Yamauchi et al, 2001). This leads to decreased 
triglyceride content of muscle, which has been associated with improved insulin 
sensitivity (Boden et al, 2002). The presence of adiponectin also has a similar impact 
on hepatic triglyceride content (Yamauchi et al, 2003), which also improves insulin 
sensitivity and hepatic glucose output. Therefore, adiponectin may of future 
therapeutic benefit in reversing some of the metabolic features of the insulin resistant 
state. 
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d. Leptin 
Leptin is a 16 kDa protein secreted by adipocytes in proportion to adipocyte mass. 
The main role of the peptide hormone leptin is to regulate energy metabolism, 
predominantly by signalling to the hypothalamus and causing a reduction in food 
intake and subsequent weight loss. Leptin deficiency (Montague et al, 1997) and 
defects in the leptin receptor (Clement et al, 1998) are rare but are associated with 
extreme obesity and insulin resistance from an early age. However, the majority of 
human obesity is associated with high rather than low levels of leptin. This has 
indicated the possibility that common obesity is a leptin-resistant state, which may be 
due to a failure of leptin in crossing the blood-brain barrier. Administration of leptin to 
a group of obese subjects resulted in significant weight loss (Heymsfield et al, 1999). 
However, in order to achieve this, serum leptin concentrations 30-fold higher than 
normal were necessary.  
 
 
1.3.5 Body fat distribution and insulin resistance 
The gender differences in body fat distribution were first described in 1947 by Vague 
et al. who reported the phenomena of gynoid obesity in females and android obesity 
in men. It was also proposed that these phenotypes were associated with different 
cardiovascular risk profiles. 
 
Since then it has become clear that visceral obesity is more closely associated with 
insulin resistance, hyperlipidaemia and type 2 diabetes. Positive correlations have 
been demonstrated between volume of visceral adipose tissue and fasting plasma 
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insulin concentrations (Despres et al, 1989). A number of studies have also 
documented the negative correlations between CT measured visceral fat mass and 
glucose disposal as measured by the hyperinsulinaemic-euglycaemic clamp 
technique (Rattarasarn et al, 2003). 
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1.4 The metabolic syndrome 
1.4.1 Introduction  
With the increasing availability of insulin assays in the 1960s, associations between 
hyperinsulinaemia and both hypertension (Welborn et al, 1996) and coronary heart 
disease (Stout et al, 1969) were noted. More than a decade later, data from relatively 
small cross-sectional studies (Modan et al, 1985; Zavaroni et al, 1989) sparked 
further interest in the role of hyperinsulinaemia and insulin resistance in CVD. In his 
Banting lecture of 1988, Reaven coined the term “Syndrome X” to describe 
clustering within subjects of cardiovascular risk factors thought to be underpinned by 
resistance to insulin-mediated glucose uptake.  “Syndrome X” has been referred to 
as “metabolic syndrome X” by many authors in order to avoid confusion with “cardiac 
syndrome X” (microvascular angina). It has also been referred to as “the insulin 
resistance syndrome” (Haffner et al. 1992), and more simply, as “the metabolic 
syndrome” (Alberti et al. 1998).  
 
 
1.4.2 Diagnostic criteria 
Since Reaven‟s Banting lecture, a number of other associations of insulin resistance 
have been suggested. The features of syndrome X, as proposed by Reaven 
(Reaven 1997) are numerous and varied depending on the defining body. In order to 
encourage an integrated rather than compartmentalised clinical approach to primary 
prevention of CVD, there have been three main attempts to define diagnostic criteria 
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for the metabolic syndrome. These definitions are compromised by the lack of 
standardisation across centres of insulin assays. 
 
Though the constituents are similar for these sets of guidelines, there are notable 
differences that may have important effects on population prevalence. The World 
Health Organisation (WHO) (Alberti et al. 1998) criteria require either proven glucose 
intolerance or for a euglycaemic clamp to have been performed, while the Adult 
Treatment Panel (ATP III) criteria need no measurement of insulin sensitivity or 
abnormality of blood glucose if other criteria are met. In the European Group on 
Insulin Resistance (EGIR) (Balkau et al. 1999) and ATPIII definitions, the blood 
pressure thresholds are lower, while the diagnosis of central obesity does not require 
a measurement of hip circumference and microalbuminuria is not included.  
 
 
1.4.3 Prevalence of the metabolic syndrome 
When the WHO set of criteria is applied to the EGIR database of 1500 non-diabetic, 
normotensive European adults, a prevalence of 15.6% is derived (Beck-Nielsen et al. 
1999). Subsequent application of diagnostic guidelines to other datasets has yielded 
a prevalence of between 7% and 30% using WHO criteria and between 1% and 22% 
using EGIR criteria, with only limited similarities in ranking of prevalence across 
studies ((Balkau et al, 1999). In the Botnia study, a large study of Finnish and 
Swedish families designed to identify early metabolic features in families with type 2 
diabetes, the prevalence of the metabolic syndrome was 10% (females) and 15% 
(males) in subjects with normal glucose tolerance between the ages of 35 and 70 
years. Insulin resistance was determined using HOMA IR, with the metabolic 
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syndrome diagnosed if the subject had insulin resistance in the highest quartile of 
the HOMA IR index in combination with two of the criteria detailed in table 4 (WHO 
criteria). In patients with type 2 diabetes, the prevalence of the metabolic syndrome 
was 78% (females) and 84% (males). A recently reported cross sectional study of 
more than 8000 members of the non-institutionalised civilian US population aged 20 
years and over, the data having been collected as part of the National Health and 
Nutrition Examination Survey (NHANES) III survey between 1988 and 1994, 
demonstrated a prevalence of the metabolic syndrome, unadjusted for age, of 
21.8%, using the ATP III criteria (NIH 2001). Perhaps most ominously, a prevalence 
of 6.7% was observed in subjects aged 20-29 years, a figure that is most likely 
greater now given the increasing problem of obesity, while application of these 
findings to census data from two years ago suggests that as many as 47 million US 
residents have the metabolic syndrome (Ford et al. 2002). 
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1.5 Obesity, insulin resistance and liver function tests 
Recent research has suggested that a degree of liver disease may accompany the 
physical states of obesity, insulin resistance and type 2 diabetes. Non-alcoholic fatty 
liver disease (NAFLD) is a term used to describe a spectrum of pathological changes 
that may occur in the liver in association with obesity and insulin resistance. It is 
defined as the accumulation of intra-hepatic lipids, primarily in the form of 
triacylglycerols in individuals who do not consume significant amounts of alcohol 
(<20 g ethanol/day), and in whom other causes of steatosis have been excluded 
(McCullough et al, 2004). It is recognised that a spectrum of diseases may be 
present, ranging from steatosis alone (type 1), steatosis plus inflammation (type 2), 
steatosis plus hepatocyte injury (type 3), and steatosis plus sinusoidal fibrosis (type 
4). The most severe forms of the condition are referred to as non-alcoholic 
steatohepatitis (NASH), and this can ultimately lead to cirrhosis or hepatocellular 
carcinoma. 
 
The prevalence of NAFLD in type 2 diabetes and obesity is unknown. It has been 
estimated that the prevalence of NAFLD in the obese ranges from 50-90%, 
compared to 20-40% in the general population (Clark et al, 2002). Nonalcoholic 
steatohepatitis accounts for about 20% of NAFLD (estimated prevalence of NASH in 
western countries is 2% to 3%) and might be the cause of approximately 80% of 
cryptogenic cirrhosis (Ratziu et al, 2002). 
 
In a recent study (Seppala-Lindroos et al, 2002) directly determined liver fat content 
was shown to correlate with several features of insulin resistance in normal weight 
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and moderately overweight subjects, independent of BMI and intra-abdominal or 
overall obesity. However, direct measurements of liver fat require ultrasound, 
computed tomography scan, or proton spectroscopy, and such techniques are 
unlikely to be recommended for this purpose in routine clinical practice. Fortunately, 
circulating concentrations of a number of variables appear to give insight into the 
extent of liver fat accumulation. Among these are γ-glutamyltransferase (GGT), 
alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Of these 
three, ALT is the most specific marker of liver pathology and appears to be the best 
marker for liver fat accumulation (Tiikainen et al, 2003). In addition, circulating 
concentrations of plasminogen activator inhibitor-1 may give insight into the extent of 
liver fat content (Festa et al, 2003) but, unlike ALT, its measurement is perhaps not 
as simple, standardized, or routinely available in laboratories. 
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1.6 ENDOTHELIAL DYSFUNCTION  
1.6.1 Endothelial function and dysfunction – definitions 
Vascular endothelial cells play a vital role in maintaining cardiovascular homeostasis 
in health. Until recently it was thought that these cells simply acted as an inert barrier 
between the vessel wall and lumen. Recent work has shown that this is not the case, 
the endothelium secreting a number of agents that are pivotal in the maintenance of 
vessel tone, platelet aggregation and coagulation (Stehouwer et al, 1997). 
 
The key feature of endothelial dysfunction is reduced availability of vasoactive 
substances, with or without increased vasoconstricting agents, which leads to 
impairment of endothelium-dependent vasodilation (Lerman et al, 1992).  Endothelial 
dysfunction coexists with insulin resistant states, and many of the mechanisms 
underlying acquired insulin resistance may also contribute to endothelial dysfunction. 
Endothelial dysfunction is also thought to be an important predisposing factor in the 
development of atherosclerosis and cardiovascular disease (Ross et al, 1993). 
 
 
1.6.2 Mediators of endothelial function in health 
One of the most important roles of the endothelium is its ability to facilitate 
vasodilatation. A number of factors are essential for endothelium-dependent 
vasodilatation, and their biological effects on vasculature have been extensively 
investigated. 
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a. Nitric Oxide (NO) 
Nitric Oxide is synthesised within endothelial cells during conversion of L-arginine to 
L-citrulline (Vallance et al, 2001) by the endothelial form of nitric oxide synthase 
(NOS), termed eNOS. This process requires numerous cofactors including 
nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide, flavin 
adenine dinucleotide, tetrahydrobiopterin and calmodulin. 
 
The half-life of NO is less than 4 seconds and it is rapidly metabolised to nitrite and 
then nitrate before being excreted in the urine (Moncada et al, 1993). NO passes 
from the endothelial cell to the vascular smooth muscle cell by diffusion. Once in the 
smooth muscle cell it activates guanyl cyclase, leading to an increase in guanosine-
3,5-monophosphate concentrations, and a reduction in smooth muscle tone and 
vasodilation (Vallance et al, 2001). 
 
NO synthesis is blocked in the experimental setting by the use of L-arginine 
analogues. These act as competitive inhibitors of the metabolic pathway catalysed 
by eNOS. 
 
Accelerated degradation of NO by reactive oxygen species generated by oxidised 
LDL-c or increased production of superoxide anion (Kojda et al, 1999), is probably 
the major mechanism impairing NO bioavailability in states of CVD (Behrendt et al, 
2002). Decreased formation of NO as a result of inhibition of eNOS may also play a 
role. 
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b. Insulin 
In addition to having multiple metabolic properties, insulin is also thought to have a 
direct role on the vascular endothelium. It has been suggested that insulin may have 
a direct effect on endothelial NO production and therefore on vascular tone. Initial 
observations demonstrated that insulin has a vasodilating effect within skeletal 
muscle and this effect was noted to be impaired in states of insulin resistance such 
as obesity and hypertension (Chen et al, 1996). Physiologically, skeletal muscle 
vasodilatation may be beneficial in that blood flow is diverted to target tissues, 
facilitating insulin delivery and consequent glucose disposal. An NO-mediated 
mechanism was proposed following studies investigating the effect of infusing the 
NOS inhibitor L-NG-monomethyl arginine citrate (L-NMMA) on forearm blood flow pre 
and post euglycaemic hyperinsulinaemic clamp (Scherrer et al, 1994). It was noted 
that reductions in forearm vasodilatation were greater during hyperinsulinaemia, than 
at baseline, suggesting that blocking NO production has a negative effect on insulin-
mediated vasodilatation. Similar results were achieved investigating the effect of L-
NMMA on insulin-mediated increase in leg blood flow (Steinberg et al, 1994). Further 
studies in healthy volunteers demonstrated a correlation between insulin sensitivity 
and forearm vasoconstrictor responses to infused L-NMMA (a surrogate for basal 
NO production) (Petrie et al, 1996). Mechanistically, studies on cultured human 
aortic endothelial cells indicate that there are similarities between post-receptor 
signalling pathways utilised by insulin to upregulate both glucose transport into cells, 
and endothelial nitric oxide synthase activity. Briefly, PKB is phosphorylated 
following recruitment of PI3-kinase to IRS-1. Activated PKB phosphorylates 
endothelial nitric oxide synthase, upregulating NO production (Salt et al, 2003). 
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c. Endothelium derived hyperpolarising factor (EDHF) 
While NO has been shown to be an important endothelium-dependent mediator of 
vascular tone in relatively large arteries and large arterioles, there are certain 
arteries in which endothelium-mediated vasodilatation is predominantly effected by 
endothelium-dependent hyperpolarisation of vascular smooth muscle cells. This 
hyperpolarisation and endothelium-dependent vasodilatation persists in the presence 
of inhibitors of eNOS (Garland et al, 1992). These findings suggest that a separate 
mechanism is responsible for endothelium-dependent vasodilatation in these 
arteries. The exact identity of the chemical involved in this mechanism is unclear at 
present. The relative importance of the EDHF mediated mechanisms alters with 
vessel size, and appears to increase as vessel size decreases (Shimokawa et al, 
1996; Urakami-Harasawa et al, 1997). 
 
A key feature of the EDHF mechanism is hyperpolarisation of the of the smooth 
muscle cell membrane mediated by the vascular endothelium. In the smooth muscle 
cell, hyperpolarisation of this membrane reduced both the open probability of 
voltage-dependent Ca channels, leading to a decrease in intracellular Ca 
concentration, and a reduction in smooth muscle tone, producing vasodilatation 
(Nelson et al, 1990). 
 
 
1.6.2 Assessment of endothelial function 
As greater emphasis has been placed on the role of endothelial function in the 
pathogenesis of disease, a number of methods have evolved for the assessment of 
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endothelial function in humans. The main aims of these developing techniques are 
the detection of endothelial dysfunction and the prevention of clinical disease 
processes. 
 
Endothelium-dependent vasomotion is the most widely used clinical endpoint for 
assessment of endothelial function. This involves stimulation of endothelial release 
of NO and other vasoactive compounds, and often a comparison of vascular 
responses to endothelium independent dilators such as nitroglycerine. 
 
The techniques for measurement of endothelial function fall into four main 
categories: coronary circulation; endothelial function in other conduit vessels; 
microvascular endothelial function (in resistance vessels); and the analysis of 
circulating factors.  
 
 
a. Endothelial function in the coronary vascular bed 
Initial clinical studies of endothelial function were performed in the coronary 
circulation. Patients with angiographically proven CAD displayed a paradoxical 
vasoconstrictor response to locally infused acetylcholine (Ludmer et al 1968; Vita et 
al, 1990). It has also been shown that shear stress induced by increases in coronary 
blood flow lead to reduced FMD in patients with established CAD (Cox et al 1989; 
Drexler et al 1999). Although the presence of endothelial dysfunction in the coronary 
circulation has prognostic implications for the development of CAD, these 
investigations are only suitable to perform on persons who require angiographic 
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studies for clinical reasons, and are not suitable techniques for repeated evaluations 
of vascular function. 
 
b. Endothelial function in conduit vessels 
The term “conduit vessel” is used to refer to larger arteries, such as the coronary, 
brachial, and femoral arteries. These vessels are most prone to atherosclerotic 
changes leading to cardiovascular disease. 
 
Flow mediated dilatation; The limited clinical use of coronary vascular studies 
necessitated the development of alternative methods of assessing the endothelium. 
As a result, it has been demonstrated that impaired coronary endothelial responses 
found in those with cardiovascular risk factors are mirrored in the peripheral 
vasculature (Panza et al 1990; Linder et al 1990). Measurement of flow-mediated 
dilatation using ultrasonography has therefore been developed. This technique is 
based on the principle that increases in tissue blood flow caused by transient 
ischaemia leads to shear stress, and in turn increases in the release of NO and other 
vasoactive substances. The ischaemic stimulus is created by placing a blood 
pressure cuff, inflated to >50 mmHg above the systolic pressure, on the forearm. 
Subsequent release of the cuff leads to reactive hyperaemia and transient brachial 
artery dilatation. This non-invasive, relatively simple technique is useful in large 
populations, and for repeated assessments of endothelial function. However, there 
are a number of mechanistic and biological factors that can affect these 
measurements, and limit the use of this technique (Corretti et al, 2002). 
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Assessment of the pulse wave; Although initially described and used in clinical 
practice since the 19th century, assessment of the pulse wave as a measure of 
vascular health has undergone something of a renaissance in recent years. 
Technology now allows estimation of the ascending aortic pressure wave from that 
assessed peripherally in the radial artery.  
 
The central arterial pulse is composed of two major components; a forward travelling 
wave generated by left ventricular systolic contraction, and a reflected wave arriving 
from the periphery. The reflected wave adds to the amplitude of the forward 
travelling wave by the principle of superimposition. The properties of the forward 
travelling wave are dependent on the physical and mechanical properties of the 
central large arteries. The properties of the reflected wave are dependent on the 
physical and mechanical properties of the whole arterial tree, the transmission 
velocity of the incident wave, and the distance to the major reflecting sites. 
 
An increase in the stiffness of arterial walls causes an increase in the transmission 
velocity of both the incident pressure wave and the reflected wave. Arterial stiffness 
is a term used to describe overall rigidity of the arterial walls, and can be measured 
by different methods. 
 
Pulse wave velocity (PWV): This measurement is determined by the time taken for 
the pulse wave to traverse the distance between two fixed measuring points. The 
PWV is derived as: 
 Distance / Time in m/s 
where m is metres and s is seconds. 
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There are a number of potential confounding factors to be considered when 
measuring the PWV. The measurement required is of the velocity of the forward 
wave, and reflected waves may interfere with the accuracy of the calculation. 
Measurements must therefore be taken from the foot of the waveform (the upstroke 
of the pressure wave), which is generated entirely by the forward wave. 
 
Another potential problem is the accuracy of the distance between measuring points. 
Out of necessity, the measurement (using standard techniques) is an approximation 
of the actual distance, as the actual length of the artery cannot be measured. This 
particular problem is addressed with new techniques for the measurement of PWV, 
using magnetic resonance imaging (Bradlow et al, 2007). 
 
A simple and well-established method of measurement of the PWV is to use a semi-
automated device for analysis of the pressure waveforms at the two measurement 
sites. The upstroke of the wave is identified at each of these sites, and the time 
between the two upstroke points is measured. Once the distance between 
measuring points has been identified and entered, the velocity of the pulse wave is 
calculable by the software. An average of multiple measures is made (between 10 
and 25). An advantage of this method is that the pressure waves measured at each 
point stem from the same ventricular systolic contraction. This eliminates potential 
errors arising from beat-to-beat variability of cardiac output and consequent 
variability of the pulse wave morphology. 
 
Pulse wave analysis: The pulse pressure wave is formed from the combination of 
the incident wave and waves reflected back from the periphery, and this can be 
 65 
measured and analysed using applanation tonometry and appropriate software. 
The augmentation index (AIx) is a measure of the effect of wave reflection on the 
second systolic peak, and is thus one measure of the additional load to which the 
left ventricle is subject as a result of wave reflection. It is calculated as the 
increment in pressure from the first shoulder in the ascending aortic pressure wave 
to the peak of this wave expressed as a percentage of the ascending aortic 
pressure wave. The time of arrival of the reflected waves is heavily dependent on 
the PWV, which is influenced mostly by arterial stiffness. Early arrival of the 
reflected waves, which occurs with arterial stiffness, coincides with systole placing 
greater pressure on the left ventricle. Alternatively, if the arrival of the pulse wave 
coincides with diastole (as is the case with an elastic aorta) this can enhance 
coronary arterial filling. 
 
A number of studies have been performed to assess the reproducibility of performing 
SphygmoCor Pulse Wave Analysis measurements. These studies have included 
healthy subjects (Siedenhofer et al, 1999; Filipovsky et al, 2000), hypertensive 
(Wilkinson et al, 1998) patients and renal pre-dialysis and dialysis (Savage et al, 
2002) patients. The inter-observer variation and temporal variation was satisfactory 
in all groups.  
 
c. Endothelial function in the microvasculature 
Ex vivo tests – Wire myography: In 1972 Bevan and Osher first suggested a 
technique for the investigation of the properties of small arteries with diameters down 
to approximately 100um. Mulvany and Halpern developed this technique, with the 
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method for investigation of a single vessel of diameter 100-1000um being published 
in 1977. Over subsequent years this technique has been developed to allow 
investigation of initially two and then four vessels simultaneously. This technique 
allows vessels to be mounted as cylinder or ring preparations, using a relatively 
atraumatic technique to preserve vascular endothelial functional integrity. The 
technique allows measurement of isometric responses and is termed Mulvany-
Halpern (wire) myography. A detailed description of the practical aspects of this 
technique can be found in section 2.8. 
 
Venous occlusion plethysmography (Whitney et al, 1953; Greenfield et al, 1963): 
This is a well-established technique for the study of the microcirculation. With a 
catheter placed in the brachial artery, drugs are infused into the forearm circulation, 
and blood flow is measured non-invasively by means of strain gauge 
plethysmography. The technique is based on the principle that obstruction of venous 
outflow in the setting of non-disturbed arterial flow, leads to an increase in limb 
volume that is directly proportional to the rate of arterial inflow. This highly 
reproducible technique has shown that many traditional cardiovascular risk factors 
such as hypertension (Panza et al, 1990), diabetes (Creager et al, 1990), and 
smoking (Heitzer et al, 1996) are associated with reduced forearm blood flow. The 
drawbacks of this technique are that it is invasive, which limits its use in large-scale 
studies or those requiring repeated measurements.  
 
Laser Doppler techniques: Laser Doppler techniques, which measure skin blood 
flow, have also emerged as methods for assessing microvascular function. These 
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techniques have evolved as the need for non-invasive tools for the assessment of 
vascular function has increased. 
 
Laser Doppler is based on the principle that light undergoes changes in wavelength 
when it hits moving blood cells. The magnitude and frequency distribution of these 
changes in wavelength are related to the number and velocity of red blood cells. 
Therefore, cutaneous microvascular blood flow can be measured as it is related to 
the properties of the reflected light. 
 
There are two techniques available for measuring cutaneous blood flow. Laser 
Doppler flowmetry uses a single probe which records blood flow in a small volume of 
1mm or less. The main drawback of this technique is the inherent variability in 
different areas of a tissue, i.e. spatial variation. Laser Doppler imaging can measure 
blood flow over a larger tissue area, as the laser beam is reflected over a given 
surface area by a computer driven mirror. 
 
Laser Doppler techniques are useful for assessing microvascular responses to 
certain stimuli such as postocclusive hyperaemia, local thermal hyperaemia and 
acetylcholine iontophoresis. These measurements have been shown to be 
reproducible, but a number of issues have to be standardized to ensure 
reproducibility. It has been suggested recently however, that rather than assessing 
specific markers of endothelial function such as NO, these techniques allow 
assessments of global microvascular function (Berghoff et al, 2002). 
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d. Peripheral markers of endothelial health 
Markers of thrombosis: Under physiological conditions, the endothelium prevents 
thrombus formation. However, endothelial damage leads to the transformation of the 
endothelium from an anti-coagulant to a procoagulant environment, due to changes 
in the expression of a variety of molecules, such as tissue factor, plasminogen 
activator inhibitor (PAI-1) increased secretion of von Willebrand factor (vWf). There is 
evidence to suggest that serum concentrations of vWf are associated with risk of 
future MI and stroke (Folsom et al, 1997; Smith et al, 1997) 
 
Markers of inflammation: Atherosclerotic disease is known to be associated with 
systemic inflammation, which is a key player in the development and progression of 
atherosclerosis (Ross et al, 1999). Baseline plasma levels of intercellular adhesion 
molecule-1 (ICAM-1) and E-selectin have been shown to be associated with 
increased cardiovascular risk in healthy populations (Hwang et al, 1997), and 
adverse outcomes in those with established CAD (Blankenberg et al, 2001). C-
reactive protein, an acute phase reactant synthesized by the liver and vascular 
smooth muscle cells has emerged as a potential marker for cardiovascular risk 
(Ridker et al, 2003; Pearson et al, 2003). 
 
 
1.6.3 Endothelial dysfunction and cardiovascular risk 
Endothelial dysfunction is associated with classical cardiovascular risk factors such 
as hypertension, dyslipidaemia and diabetes (Busse et al, 1996; Panza et al, 1993; 
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De Vriese et al, 2000). A strong association between insulin resistance, obesity and 
endothelial dysfunction has also been demonstrated (Steinberg et al, 1996). 
 
A number of small studies have evaluated the prognostic value of endothelial 
dysfunction. Three studies have assessed the association between endothelial 
dysfunction in the coronary circulation and CVD, and in each of these cohorts 
endothelial dysfunction predicted the occurrence of CVD events (Halcox et al, 2002; 
Al Suwaidi et al, 2001; Schachinger et al, 2000). In contrast, Heitzer et al (2001) 
observed that forearm bloodflow responses, rather than coronary artery responses to 
intra-arterial acetylcholine infusion was an independent predictor of cardiovascular 
events. Neunteufl et al (2000) observed a similar association when examining 
brachial artery FMD using ultrasound. 
 
In patients with risk factors for but no pre-existing CVD, associations were observed 
between endothelial dysfunction (assessed in the brachial artery) and subsequent 
cardiovascular events (Perticone et al 2001; Modena et al, 2002).     
 
 
1.6.4 Endothelial dysfunction and insulin resistance – underlying shared 
pathophysiology 
A robust association between insulin resistance and endothelial dysfunction in 
animals and human studies has therefore been demonstrated. Whether the two 
states are linked directly or are simply manifestations of an underlying pathology 
remains to be seen, but there are a number of factors common to both states, which 
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may contribute to the mechanistic link between them. Molecular and 
pathophysiological mechanisms underlying reciprocal relationships between insulin 
resistance and endothelial dysfunction result in a vicious cycle reinforcing the link 
between metabolic and cardiovascular disorders. There are three main factors 
associated with type 2 diabetes and insulin resistance which also predispose 
individuals to endothelial dysfunction: glucotoxicity and hyperinsulinaemia, 
lipotoxicity, and adipocytokines and inflammation.  
 
a. Glucotoxicity and hyperinsulinaemia 
Hyperglycaemia causes insulin resistance by three methods. Firstly, hyperglycaemia 
increases the production of reactive oxygen species (ROS) which are associated 
with the activation of various serine / threonine kinases. This leads to serine 
phosphorylation of IRS-1, which impairs its ability to bind and activate PI3 kinase. 
This in turn leads to diminished activation of downstream events, leading to reduced 
GLUT4 translocation and glucose transport (Furukawa et al, 2004, Hirosumi et al, 
2002). In parallel, this increased oxidative stress has a number of effects on the 
endothelium, including reducing NO bioavailability, and increasing proinflammatory 
molecules, all of which increase the likelihood of endothelial dysfunction. 
 
Advanced Glycation End Products (AGEs) also inhibit insulin-stimulated tyrosine 
phosphorylation of IRS-1 and 2, leading to impaired activation of PI3 kinase and 
reduced glucose transport. AGEs also produce ROS, which increase oxidative 
stress, impairing the function of endothelial proteins, and enhancing the formation of 
foam cells from macrophages, which lead to atherosclerosis. 
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Hyperinsulinaemia is a feature of insulin resistant states and is also an independent 
risk factor for coronary artery disease (Despres NEJM 1996). Insulin acts as a 
vasodilator at physiological doses mediated by the production of NO. However, 
insulin also stimulates the release of the vasoconstrictor endothelin-1 (ET-1) from 
endothelial cells. Increased serum levels of ET-1 have been demonstrated in insulin 
resistant subjects. In such individuals, it is hypothesised that there may be an 
imbalance between PI3 kinase and MAP kinase mediated insulin signalling 
pathways. This overdrive of MAP-kinase subcellular pathways may lead to increased 
endothelin-1 and reduced NO expression, both of which are characteristic features of 
endothelial dysfunction. 
 
The metabolic and vascular functions of insulin have been shown to be parallel both 
in healthy and diseased states. At the cellular level the signalling pathways by which 
insulin mediates glucose uptake and NO production are similar. After binding to its 
receptor, insulin promotes GLUT4 translocation in skeletal muscle and increases 
eNOS activity in the vascular endothelium. The subcellular signalling pathway 
employed to mediate this effect of insulin is the same as that central to glucose 
uptake, both featuring PI-3 kinase and Akt. This has led to the hypothesis that that 
disruption of PI3 kinase may be the unifying mechanism in insulin resistant states. 
Down regulation of PI3 kinase has been observed in skeletal muscle taken from 
insulin resistant humans (Cusi et al, 2000). 
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b. Lipotoxicity 
Elevated FFA levels in insulin resistant states are hypothesized as being another 
factor linking this with endothelial dysfunction. Again, increased FFA levels have 
been shown to cause mitochondrial dysfunction (Lowell et al, 2005; Savage et al, 
2005), which in turn increases the generation of ROS, having detrimental effects on 
insulin-mediated glucose transport and endothelium-dependent vasodilatation.  
 
FFAs have also been shown to Activate NF-ĸB, which stimulates the production of 
proinflammatory cytokines including IL-6 and TNF. In addition, accumulation of 
ceramide, a product derived from long chain fatty acids, inhibits GLUT4 translocation 
and also increases ROS, further scavenging NO. 
 
c. Cytokines and inflammation 
Both endothelial dysfunction and insulin resistance are widely known as 
proinflammatory states, and are associated with increased levels of inflammatory 
cytokines (Berg et al, 2005). The most extensively studied proinflammatory cytokine 
implicated in insulin resistance is TNF. TNF activates a variety of serine kinases 
such as JNK (Nguyen et al, 2005), which increase serine phosphorylation of IRS-1/2, 
leading to decreased activity of PI-3 kinase and Akt. TNF and IL-1 also lead to the 
activation of NF-B, which inhibits insulin-stimulated activation of eNOS (Kim et al, 
2001). TNF also stimulates the expression of other inflammatory proteins such as 
CRP and IL-6, thereby further promoting a proinflammatory environment. 
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1.7 Morbidity and mortality associated with obesity 
It is now well established that obesity is an independent risk factor for the 
development of CVD (Kannel et al, 1991), as well as being associated with many of 
the more traditional risk factors for atherosclerosis such as type 2 diabetes and 
hypertension (Chan et al, 1994). It is accepted that the obese state can also 
predispose to malignant disease and musculoskeletal conditions. 
 
 
1.7.1 Obesity and mortality 
Direct associations between obesity and disease processes are well documented, 
but the relationship between mortality and body weight is more controversial. Initial 
observational studies in males confirmed increased mortality risk with weights above 
a certain threshold, but described J-shaped curves, with increased mortality figures 
being noted in the very lean (Lew at al, 1979, Lee et al, 1993). However, after 
correction for smoking and chronic illness, no association between leanness and 
mortality was observed. These results were replicated in a female population in the 
Nurses Health Study (Manson et al, 1995). A further study (Adams et al, 2006) has 
also demonstrated that simply being overweight (BMI 25.0 to 29.9) rather than obese 
is also associated with a 20 to 40% increase in risk of death from all causes. 
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1.7.2 Obesity and type 2 diabetes 
Many cross sectional and prospective studies have confirmed the association 
between obesity and type 2 diabetes. Biennial questionnaires were sent to more 
than 50,000 male health professionals in the US for 6 years to assess the effect of 
different anthropometric variables on development of type 2 diabetes. This study 
revealed that men with a BMI > 35 had a relative risk of developing diabetes of 42, 
compared to men with BMI < 23 (Chan et al, 1994). The study also showed that BMI 
at the age of 21, and absolute weight gain during adulthood predicted the 
development of type 2 diabetes. Similar findings have been reported for females 
from data again from the Nurses Health Study (Carey at al, 1997). The risk of 
developing diabetes, in this cohort of Caucasian women aged 30-55 years at 
baseline, was 49 times higher in those with a BMI >35 than amongst women whose 
baseline BMI <22.  
 
The pattern of body fat distribution also plays a role in the development of type 2 
diabetes. A prospective study to assess risk factors for coronary heart disease 
looked at 792 men aged 54 years. This Swedish study revealed a positive and 
significant correlation between increasing waist-hip ratio and development of type 2 
diabetes, even when BMI was corrected for (Ohlson et al, 1985). The Iowa Women‟s 
Health Study, also a prospective questionnaire study, aimed to look at the 
association between body fat distribution and disease incidence in a large cohort of 
older women. Although the study was limited in that the diagnoses of diabetes were 
self-reported and prevalence may therefore be underestimated, this study did show 
that BMI, WC and WHR were significantly and positively correlated with the 
development of type 2 diabetes  (French et al, 1997). 
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1.7.3 Obesity and hyperlipidaemia 
Obesity also has a number of effects on lipoprotein metabolism. The typical pattern 
of dyslipidaemia associated with obesity tends to be that of elevated triglycerides, 
reduced HDL and small dense atherogenic LDL. The Framingham Offspring Study 
examined a cohort of 4260 male and female subjects, and revealed an inverse 
relationship between HDL cholesterol and obesity in all age groups (Garrison et al, 
1980). The study was unable to demonstrate such a clear correlation between 
obesity and LDL cholesterol. The third round of the Framingham Offspring Study in 
1996 supported the linear association between BMI and VLDL, LDL and total 
cholesterol, although the linear and inverse relationship between BMI and HDL 
cholesterol was noted to be the strongest (Lamon-Fava et al, 1996). 
 
Body fat distribution also appears to play a role in the complex dyslipidaemic picture 
that is associated with obesity. A number of small studies have demonstrated this 
association. A study of 303 white male and female subjects which measured body fat 
distribution using densitometry, revealed a positive association between centripetal 
fat and serum triglycerides, and a negative association between central adiposity 
and HDL cholesterol in female subjects (Baumgartner et al, 1987). This association 
was not demonstrated in males in this particular study. A further study which 
recruited 52 premenopausal obese females, and measured abdominal obesity using 
CT scanning, demonstrated a similar association between central adiposity and 
serum HDL cholesterol concentrations (Depres et al, 1989). A study of 512 thirty 
eight year-old European males with a wide range of anthropometric measurements, 
revealed a positive association between BMI, WC and serum total cholesterol, LDL 
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cholesterol and a negative association between anthropometric measurements and 
HDL cholesterol.  
 
 
1.7.4 Obesity and coronary artery disease 
Obesity has traditionally been associated with coronary artery disease. Until recently, 
however the role of obesity as an independent risk factor remained controversial due 
to its co-existence with other traditional risk factors such as diabetes, hypertension 
and hyperlipidaemia. Several long-term studies have more recently demonstrated 
that obesity is an independent risk factor for CVD, leading the American Heart 
Association to reclassify obesity as a modifiable risk factor for coronary heart 
disease. 
 
A cohort of 5029 male and female participants of the Framingham Heart Study was 
followed for 26 years, and results revealed obesity to be an independent predictor of 
CHD (Kannel et al, 1991). In addition, a prospective cohort study followed 115,886 
female patients in the US for 8 years and detected a positive correlation between 
higher BMI and all categories of coronary artery disease. Lastly, a post-mortem 
study published in 2002, revealed an association between central obesity and the 
development of coronary atheroma in young males (McGill et al, 2002).   
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1.7.5 Obesity and hypertension 
According to data from the NHANES III report in the US, the prevalence of 
hypertension was 2.5 times higher in men and 3 times higher in women (aged <55 
years) with a BMI 30-34.9 than in aged matches subjects with a normal BMI. In this 
cohort the prevalence of hypertension rose from 15% in the normal weight category 
to 40% in obese subjects (Brown et al, 2000). In addition the Health Survey for 
England 2003 found that mean systolic blood pressure was about 6mmHg higher in 
obese men and women than in those with a BMI 18.5 to 25. 
 
 
1.7.6 Obesity and cancer 
Cancer is one of the less recognised complications of obesity, but excess body fat is 
now known to be a significant risk factor for malignant disease. Recent studies have 
suggested that 3.4% of cancers in men and 6.4% of cancers in women are 
attributable to obesity. In both men and women obesity was associated with higher 
mortality rates from cancer of the oesophagus, colon, pancreas, gallbladder and 
kidney. Obesity has also been associated with increased risk of death from cancers 
of the uterus, ovary and breast in females, and of the stomach and prostated in men 
(Calle et al, 2003). 
 
The underlying cause of this increased risk is thought to be multifactorial. Increased 
concentrations of hormones such as insulin-like growth factor 1 (IGF1) and insulin 
promote growth and differentiation of cells. In addition, low levels of chronic 
inflammation such as those that accompany obesity also play a role in the 
development of malignant cells (McMillan et al, 2006). 
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1.8 Effects of weight loss on health 
The long-term effects of intentional weight loss on mortality and health benefits of 
weight loss remain incompletely understood, and numerous small studies have 
attempted to examine this issue. The most comprehensive evaluation of this 
information in the UK to date seems to come from a Health Technology Assessment 
(HTA) review (Avenell et al, 2004). This extensive meta-analysis included cohort and 
prospective studies that looked at the effects on intentional weight loss in obese or 
overweight (BMI > 28) adults. There were a number of outcome measures 
examined, and subjects in the 37 trials included in the analysis were followed up for 
a minimum of two years. 
 
 
1.8.1 Weight loss and mortality 
The meta-analysis included 5 studies that looked at the effects of weight loss on 
mortality (Chaturvedi et al 1995; Williamson et al 1995; Williamson et al 1999; 
Williamson et al 2000; Rumpel et al 1993).  All cause mortality was noted to be 
reduced in females with obesity related illness, regardless of the degree of weight 
loss, and in males and females with diabetes mellitus. There was no reduction in all 
cause mortality in any other group. Unintentional weight loss seemed to be 
associated with higher mortality rates, probably due to undiagnosed illness.  
 
CVD-related mortality was reduced after intentional weight loss in subjects with 
diabetes (relative risk reduction of 28%), and if weight was lost within 1 year. 
Interestingly if weight loss was slower (> 1 year), there was an increased risk of 
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CVD-related mortality. Mortality related to type 2 diabetes was reduced in males and 
females, irrespective of the timing, or the amount of weight lost. 
 
 
 1.8.2 Diabetes  
It is now incontrovertible that weight loss can prevent or delay the onset of type 2 
diabetes. Subjects enrolled in the Diabetes Prevention Study (DPS) were 
randomised to a control or intervention group, the intervention being multifactorial 
lifestyle modifications aimed at weight loss. Modest weight loss in the active group 
was associated with a 58% relative risk reduction in the incidence of type 2 diabetes 
over a 3-year period (Tuomilehto et al 2001).  
 
Similarly, the Diabetes Prevention Program (DPP) Research Group demonstrated 
that lifestyle interventions, aimed at weight reduction, led to a significant reduction in 
type 2 diabetes in a cohort of 3234 obese male and female patients, followed up for 
a period of 2.8 years (Knowler et al 2002). 
 
 
1.8.3 Lipid profile 
Thirteen studies included in the HTA review examined the effects of weight loss on 
lipid profiles (Davidson et al 1999; Hauptman et al 2000; Teupe et al 1991; Wing et 
al 1998; Hess et al 1998; O‟Leary 1980; Karason et al 1999; Gleysteen et al 1992). 
The majority of the studies were relatively small with numbers of participants ranging 
from 7 to 323 subjects. Weight loss was achieved by diet, exercise or drugs in eight 
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of the 13 studies, and by surgical interventions in the other five studies. Overall, 
weight loss was associated with significant reductions in LDL-c, triglycerides and 
total cholesterol, with greatest reductions in lipid parameters observed in association 
with maximum weight loss.  
 
 
1.8.4 Hypertension 
There were 14 studies in the review that looked at the effects of weight loss on 
hypertension. Regression analysis of these results would suggest that a reduction in 
body weight of 10 kg leads to a drop of 3.6mmHg in diastolic blood pressure. 
Although the results for systolic blood pressure did not reach statistical significance, 
there was a trend towards lower systolic blood pressure with reduced body weight. 
 
 
1.8.5 Cardiovascular Disease 
Although short-term weight loss has been demonstrated to ameliorate obesity-
related metabolic abnormalities and CVD risk factors, no prospective randomised 
studies have examined the long-term consequences of intentional weight loss in 
obese populations. The primary hypothesis of the Look AHEAD (Action for Health in 
Diabetes) study is that an intensive lifestyle intervention to reduce weight and 
increase physical activity will reduce cardiovascular morbidity and mortality. Primary 
outcome measures will include death from CVD, non-fatal myocardial infarction and 
non-fatal stroke. The planned follow-up period for this multi-centre randomised 
controlled trial is 11.5 years, with follow-up due to end in 2012 (Ryan et al, 2003).  
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1.8.6 Adverse effects of weight loss 
The beneficial effects of intentional weight loss on health are numerous. There are 
some concerns however that weight loss may be associated with adverse health 
consequences. The main issue complication which can result form rapid weight loss 
is the development of gallstones. This has been reported following weight loss as a 
result of both lifestyle intervention and bariatric surgery. 
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1.9 EFFECTS OF WEIGHT LOSS ON METABOLIC AND 
VASCULAR PARAMETERS 
1.9.1 Metabolic effects of intentional weight loss in obese, non-diabetic 
populations 
A number of groups have examined the effects of intentional weight loss in obese 
populations. The vascular and metabolic effects of weight loss using diet, exercise, 
pharmacological measures, surgery, and a combination of the above have been 
studied. The results to date are variable, with study cohorts being heterogeneous. A 
number of studies, using a variety of methods to achieve weight loss, have assessed 
the effects of intentional weight loss on serum levels of adipocytokines (Table 1.1). 
 
a. Diet only protocols 
The association of adipocytokines with obesity has been a relatively recent 
discovery, but over the past ten years there is a growing body of work looking at the 
effect of weight loss on serum and tissue levels of these substances. Bastard et al 
(2000) demonstrated reductions in serum and adipose tissue IL-6 and leptin 
following three weeks of a very low calorie diet (VLCD), in association with mean 
weight loss of 3kg, and increased insulin sensitivity in a group of obese 
postmenopausal women. The study did not reveal any change in TNF levels 
following weight loss.  
 
In addition, a group of obese subjects were studied by Raitakari et al (2003). These 
67 male and female subjects lost an average of 11kg after a 6-week period of VLCD 
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(580 kcal/day). Significant reductions in total cholesterol, LDL-c, oxidised LDL and 
CRP were achieved following weight loss, in combination with significant increases 
in serum adiponectin levels.  
 
No change in serum adiponectin levels was observed following a 12-week period of 
low calorie diet (1200kcal/day) in a group of 15 females with an android pattern of 
obesity (Manigrasso et al, 2005). This was despite a median reduction in BMI of 8% 
and significant increase in insulin sensitivity as measured by the HOMA index. 
 
A further study examined the effects of 6 months of calorie reduction in 12 male and 
female subjects. Significant reductions in body weight (mean reduction 6.8kg) and 
body fat percentage were associated with statistically significant improvements in 
total and LDL cholesterol, and insulin sensitivity. (Dengel et al, 2006) 
 
b. Combined diet and exercise protocols 
The effects of a combination of diet and exercise on the metabolic abnormalities 
associated with obesity have also been studied. Janssen et al (2002) compared the 
effects of a diet only approach versus diet and aerobic exercise or diet and 
resistance exercise in 38 postmenopausal women. A mean weight loss of 10kg after 
a 16-week programme in all three groups was associated with significant reductions 
in total and LDL cholesterol levels, with no obvious additional benefits conferred to 
those in the exercise groups.  
 
In contrast, 6 months of weight reduction using diet and exercise led to no 
improvements in LDL cholesterol, but increased HDL cholesterol concentrations in 
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24 obese male and female subjects. This also resulted in significant reductions in 
serum ICAM-1, but not in vWf or vCAM (Hamdy et al, 2003).   
 
However, a randomised single-blind trial (Esposito et al, 2003), which led to a mean 
weight loss of 14kg, did not demonstrate significant changes in lipid profile in 60 
postmenopausal females following 2 years of diet and exercise. Compared to the 
placebo arm of this study, weight loss in this setting was associated with significant 
reductions in serum concentrations of IL-6, and CRP, whilst adiponectin levels were 
significantly increased. 
 
c. Diet and pharmacological agents 
Two studies have looked at the effect of a combination of diet and orlistat on weight 
loss and its associated adverse metabolic profile. Bergholm et al (2003) studied the 
effects of 3-6 months of dietary with and without the addition of orlistat on weight, 
metabolic and vascular parameters in 47 obese subjects. Reductions in weight were 
7.3kg and 7.4 kg in the orlistat and diet only groups respectively. Interestingly there 
was a significant reduction in serum LDLc concentration of 0.48+/-0.15mmol/l in the 
orlistat group but not in the placebo group. A similar study by Brook et al (2004) also 
revealed significant reductions in plasma LDL-c, leptin and CRP concentrations after 
a mean body weight reduction of 6.6%. 
 
d. Multidisciplinary approach 
A multidisciplinary approach to achieve weight loss is often used in clinical practice. 
A combination of diet, exercise and, in some cases, local liposuction was employed 
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to achieve an average weight loss of 9.8kg in 56 obese female subjects (Ziccardi et 
al, 2002). This led to significant reductions in levels in serum levels of TNF, IL-6, p-
selectin, ICAM and VCAM. There were no observed differences in cholesterol profile 
in these subjects after weight loss. Another multidisciplinary programme consisting of 
diet, exercise and liposuction surgery over one year resulted in a 10% reduction in 
body weight in 20 pre-menopausal women (Nicoletti et al, 2003). This was 
associated with significant reductions in cytokine concentrations. 
 
 
1.9.2 Vascular effects of weight loss in obese non-diabetic subjects 
A number of the studies described above also examined the effect of weight loss on 
measures of vascular function. The results of these are outlined below. 
 
a. Diet only 
Only two studies employing solely dietary methods for weight loss looked at the 
effects on vascular function. Raitakari et al (2004) looked at the effect of weight loss 
on two parameters of vascular function. This study demonstrated that reduction of 
body weight in 67 obese men and women was associated with significant 
improvements in brachial artery flow-mediated dilation (FMD). In contrast, there were 
no observed differences in endothelium independent function as assessed by 
vascular responses to sublingual GTN spray. 
 
These results contrast with those of Dengel et al. where there was no noted 
improvement in brachial artery FMD or endothelium independent vasodilatation (EID) 
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after weight loss. In addition, no significant differences in carotid intima media 
thickness (IMT) were noted after a period of weight loss. 
 
b. Diet and exercise 
Only one study has examined the combined effects of diet and exercise on vascular 
function. A study by Hamdy et al (2003) revealed that a 6-month programme of diet 
and exercise caused significant improvements in macrovascular endothelial function 
as measured by flow-mediated dilatation in 24 subjects. However, microvascular 
reactivity measured by laser Doppler imaging remained unchanged. 
 
c. Diet and pharmacological agents 
Dietary measures and orlistat have been used in 2 studies to assess vascular 
responses to weight loss. Brook et al. studied the effect of diet with or without these 
two weight loss modalities in 43 otherwise healthy male and female subjects. Mean 
weight reduction of 6.6kg was not associated with any improvement in brachial artery 
FMD. 
 
Assessment of forearm resistance artery endothelial function was measured by 
quantifying bloodflow responses to intraarterial acetylcholine and SNP (endothelium-
dependent and independent responses respectively) by Bergholm et al (2003). 
Despite similar weight losses in both arms of the study (diet and placebo vs diet and 
orlistat), significant improvements in forearm bloodflow were seen in the group 
receiving orlistat, but not in the placebo treated group. 
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d. Multidisciplinary approach   
Ziccardi et al (2002) achieved significant weight loss after a year-long 
multidisciplinary approach in a cohort of obese women. This led to significant 
improvements in blood pressure responses and blood viscosity following an 
intravenous infusion of L-arginine. These results were mirrored by Nicoletti et al 
(2003), who revealed similar improvements in endothelial function following one year 
of weight loss. 
 
 
1.9.3 Metabolic and vascular effects of intentional weight loss in type 2 
diabetes 
The majority of studies designed to examine the effects of weight loss have, until 
recently, focused on subjects without diabetes. However, over the past few years, a 
number of groups have studied the effects of weight loss in patients with type 2 
diabetes. The majority of these studies have looked at the effects of intentional 
weight loss on insulin sensitivity and circulating markers in type 2 diabetes, rather 
than dynamic vascular function testing. 
 
In 1999, Halle et al demonstrated the effects of weight loss in 20 obese males with 
type 2 diabetes. A four-week intervention comprising calorie restriction to 1,000kcal 
day, and 30 minutes of aerobic exercise daily, led to significant reductions in weight, 
glycaemic control and fasting insulin levels. These changes were associated with 
reductions in serum total and LDL cholesterol and serum leptin concentrations. The 
changes in serum leptin concentration correlated with reductions in total cholesterol 
and triglycerides, but not with changes in glycaemic control, LDL or HDL cholesterol. 
 88 
The results of a similar study were published in 2003. Monzillo et al demonstrated 
that a 6-month programme of diet and exercise lead to a mean reduction in weight of 
6.9kg, in association with significant reductions in serum leptin, and IL-6. Of the 24 
participants in this study, eight had type 2 diabetes, and weight loss lead to 
increased adiponectin levels only in this subgroup. In contrast, weight loss of 4.5 +/- 
0.6kg in 33 postmenopausal females, following a regime of diet only or diet and 
exercise for 14 weeks, led to reductions in serum leptin and CRP levels 
(Giannopoulou et al, 2005). This intervention was not however, associated with any 
increase in serum adiponectin levels. 
 
Interestingly, a randomised double blind placebo-controlled parallel comparison of 
sibutramine and placebo carried out in 48 patients with type 2 diabetes, showed 
similar results. Six months treatment with sibutramine was associated with an 
average weight reduction of 2.5 kg. Insulin sensitivity was enhanced (assessed using 
the steady-state plasma glucose level) but no changes in serum CRP or adiponectin 
were observed after a period of weight loss (Hung et al, 2005). 
 
Barinas Mitchell et al (2006) observed the effect of a yearlong programme of diet, 
exercise and orlistat or placebo in a cohort of subjects with type 2 diabetes. Weight 
loss was similar in both groups, with significant improvements in PWV and reduced 
serum concentrations of TNFα, IL-6, PAI-1, and CRP.  
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Table 1.1: Weight loss intervention studies 
 
Study  n 
Age 
(yrs) 
M/F 
BMI 
(kg/m
2
) 
T2DM 
(Y/N) 
Intervention  
Insulin 
sensitivity 
measurement 
Endothelial 
function 
measurements 
Metabolic 
measurements 
Body 
composition 
measurements 
Mean 
reduction 
body 
weight 
(%) 
Main findings 
 
Barinas-
Mitchell 
et al. 
2006 
38 
20 -
70 
M+F 
34 ± 
5.2 
37± 8 
Y 
Diet, 
exercise, 
placebo vs. 
orlistat 
(1 year) 
Fasting 
plasma insulin 
PWV, IL-6, 
TNFα, CRP, 
PAI-1, 
Fibrinogen 
FPG, HbA1c, 
HDL-c, LDL-c, 
Anthropometry 
7.8 Improved PWV. 
Reduced TNFα, IL-
6, PAI-1, CRP. 
Improved LDL-c 
and HbA1c 
 
Bastard 
et al. 
2000 
14 
45  
4 
F 
39.5  
1.1 
N 
VLCD 
(3 weeks) 
FIRI 
Leptin, IL-6, 
TNF, CRP 
FPG 
BMI, WHR, 
DXA 
5 Significant 
reductions in body 
fat mass,  leptin 
and IL-6 after 
weight loss; 
increased insulin  
sensitivity 
 
Bergholm 
et al. 
2003 
47 
39  
1 
F 
32.3  
0.4 
N 
Diet + 
orlistat / 
placebo 
3-6 months 
Fasting insulin 
Forearm blood 
flow responses 
to Ach and 
SNP 
FPG, HDL-c, 
LDL-c, 
triglycerides, 
FFAs 
BMI, WC, body 
fat estimation 
by 
bioimpedance 
8.3 Improved forearm 
responses to Ach 
and reduced LDL-c 
in orlistat group but 
not in placebo 
group. 
 
Brook et 
al. 
2004 
43 
18 – 
50 
>27 N 
Diet and 
orlistat (12 
weeks) 
Fasting insulin 
Brachial artery 
FMD, CRP, 
leptin 
FPG, TC, LDL-
c, HDL-c 
BMI, WC, HC, 
body fat 
estimation from 
skin fold 
thickness 
measurements 
6.6 
Reductions in LDL-
c, fasting insulin 
and leptin. No 
improvement in 
brachial FMD 
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Dengel et al. 
2006 
12 
54.9 
 3.9 
M + 
F 
30.3 
 3.7 
N 
Diet 
(6months) 
IVGTT  
TC, LDL-c, HDL-
c, FPG, TGs 
BMI, 
DXA 
7.9 
Significant reductions in 
BMI and body fat %; 
improved TC, LDL-c, TGs; 
improved insulin sensitivity. 
No improvements in 
endothelial function 
 
Esposito et al. 
2003 
120 
34.2 
± 4.8 
F 
35.0 
± 2.3 
N 
Diet and 
exercise (2 
years) 
Fasting 
insulin 
HOMA 
Il-6, IL-18 
Adiponectin, 
CRP 
FPG, TC, HDL-c, 
trigs, FFAs 
BMI, 
WHR 
15 Mean weight reduction 
14kg; significant 
improvements in all 
measurements. 
 
Giannopoulou 
et al. 
2003 
33 
50-
70 F 
>30 Y 
Diet alone (D), 
exercise alone 
(E), diet and 
exercise (D+E) 
Fasting 
insulin 
TNF, IL-6, 
Adiponectin, leptin, 
resistin, CRP 
HbA1c, TC, 
HDL-c, LDL-c, 
TGs 
ADP, 
MRI 
(VAT, 
SAT) 
6 
Reductions in leptin and 
CRP in  in D and D+E 
groups. 
 
Halle et al. 
1999 
 
 
20 
 
48  
8 
M 
32.9 
 3.1 
Y 
Diet and 
exercise 
(4weeks) 
Fasting 
insulin 
leptin 
FPG, 
fructosamine, 
TC, trigs, LDL-c, 
HDL-c, FFAs 
BMI 
4.4 Significant reductions in 
serum leptin and 
cholesterol profile; reduced 
leptin associated with 
reductions in cholesterol 
and trigs. 
 
Hamdy et al. 
2003 
24 
49.3 
 1.9 
M + 
F 
36.7 
 
0.94 
Y 
Diet and 
exercise (6 
months) 
Frequently 
sampled 
IVGTT 
FMD to shear 
stress and SLGTN. 
Laser Doppler 
iontophoresis; 
vWF, sICAM, 
sVCAM, PAI-1, t-
PA 
N/A 
BMI, 
WHR 
6.6 
Significant improvements 
in insulin sensitivity, FMD. 
No change in LDI 
responses to Ach or SNP. 
Hung et al. 
2005 
48 
30-
75 
M+F 
>27 Y 
Diet + 
sibutramine / 
placebo 
(6 months) 
Modified 
insulin 
suppression 
test 
Adiponectin, CRP 
HbA1c, TC, LDL-
c, HDL-c, TGs, 
FPG 
BMI, 
WHR 
7 Improved insulin 
sensitivity; no 
improvements in CRP or 
adiponectin 
  
 
Janssen et 
al. 
2002 
38 
> 30 
F 
>27 N 
Diet only (DO), diet 
and aerobic 
exercise (DA), diet 
and resistance 
exercise (DR) (16 
weeks) 
OGTT 
insulin 
sensitivity 
index 
N/A 
FPG, TC, 
trigs, HDL-c, 
LDL-c 
BMI, WC, 
WHR, MRI 
measures of 
SAT, VAT, and 
skeletal muscle 
fat 
10 
Significant reductions 
in body fat, fasting 
insulin, TC and LDL-c 
Keogh et al. 
2008 
 
99 
50.0 
 8.3 
M + 
F 
33.7 
 
4.1 
N 
Low-CHO vs. 
standard CHO diet 
(8/52) 
Fasting 
insulin 
FMD, AIx, PWV, 
ICAM-1, E-selectin, 
P-selectin, VCAM-
1, PAI-1, tPA, 
adiponectin, CRP 
FPG, TC, 
HDL-c, LDL-c, 
triglycerides 
BMI, DXA 
8 No change in FMD with 
either diet. Improved 
PWV and endothelial 
markers with both 
diets. 
Manigrasso 
et al. 
2005 
15 
47.2 
 
6.7F 
39  
7.3 
N 
Diet and exercise 
(12 weeks) 
HOMA Adiponectin, IL-10 N/A 
BMI, WHR, 
WC 
8 Significant 
improvement in insulin 
sensitivity; no change 
in adiponectin or IL-10. 
Monzillo et 
al. 
2003 
24 
49.3 
 1.9 
36.7 
 
0.9 
Y 
Diet and exercise 
(6 months) 
Frequently 
sampled 
IVGTT 
Leptin, 
adiponectin. 
Resistin, TNF, IIL-
6, CRP 
FPG BMI, WHR 
8 Significant 
improvements in 
insulin sensitivity; 
reductions in leptin; 
increased adiponectin 
only in diabetic 
subjects 
Pierce et al. 
2008 
40 
49.5 
± 2.5 
MF 
 N Diet (12/52) HOMA 
FMD, responses to 
IA infusion of Ach,  
leptin, CRP, IL-6, 
TNFα, adiponectin 
N/A 
BMI, WC, HC, 
WHR 
10.5 Improved FMD and 
forearm blood flow 
responses to IA Ach, 
correlating with degree 
of reduction in visceral 
fat. 
Plat et al. 
2007 
11 
59.0 
± 9 
31.3 
± 
2.1 
N 
Diet (6/52) and fish 
oil supplements 
(6/52) 
HOMA 
ICAM-1, E-selectin, 
CRP, MCP-1 
FPG, TC, 
LDL-c, HDL-c, 
trigs 
BMI, WHR 
10.5 Reduced fasting and 
post-prandial CRP and 
ICAM-1 following 
weight loss but not fish 
oil supplements. 
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Raitakari 
et al. 
2004 
67 
46  7 
M + F 
35.2 
 5.4 
N 
VLCD 
(6 weeks) 
Fasting 
insulin 
FMD, EID, 
CRP, adiponectin 
FPG, TC, 
LDL-c, 
HDL-c, 
Trigs 
BMI, 
WC, 
HC, 
WHR 
14 
Improvement in FMD 
which correlated with 
change in FPG 
Sharman 
et al. 
2004 
15 
33.2  
11.3 
M 
34.3 
 5.6 
N 
Randomised crossover 
trial: low fat diet vs. v 
low CHO diet (6 
weeks) 
N/A 
CRP, TNF, IL-6, ICAM-1, 
P-selectin 
N/A BMI 
7 
Both diets led to reduced 
CRP, IL-6, TNF, and 
ICAM-1. 
Wycherly 
et al. 
2008 
29 
52.4 
1.4 
M+F 
34.2 
0.9 
Y 
Calorie-reduction 
exercise 
(12 weeks) 
HOMA Brachial artery FMD, 
FPG, 
HbA1c, 
lipids 
BMI, 
WHR 
6 Improved metabolic 
parameters but no 
improvements in FMD 
after weight loss. 
Xydakis 
et al. 
2004 
80 
47.1 
0.9 
M + F 
38.3 
0.7 
N VLCD (4-6 weeks) HOMA 
Leptin, adiponectin, CRP, 
TNF 
FPG, TC, 
HDL-c 
BMI, 
WHR 
7.6 Improved insulin 
sensitivity, lipoproteins, 
leptin. No change in TNF 
or adiponectin 
Ziccardi 
et al. 
2002 
56 
35.3 
4.8 
F 
37.2 
2.2 
N 
Diet and exercise (1 
year) 
Fasting 
insulin 
Platelet aggregation and BP 
responses to L-arginine 
infusion; TNF, IL-6 p-
selectin, ICAM-1, VCAM-1 
FPG, TC, 
LDL-c, 
HDL-c, 
Trigs 
BMI, 
WHR 
10 
Improved vascular 
responses, reduced 
cytokines. 
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CHAPTER 2  
METHODS AND MATERIALS 
2.0 Summary 
This chapter outlines general protocols and methods, both clinical (physiological) 
and laboratory-based used in the studies described in this thesis. 
 
2.1 Subjects 
2.1.1 General details 
Clamp studies, arterial compliance studies, gluteal biopsies and collection of blood 
for analysis were carried out in the Clinical Investigation and Research Unit (CIRU) 
of the Western Infirmary, Glasgow. Body composition measurements were carried 
out in the Department of Human Nutrition at Glasgow Royal Infirmary. 
Anthropometric measurements and dietary follow-up took place at the Diabetes 
Centre, Glasgow Royal Infirmary  
 
The North Glasgow Universities Trust Ethics Committee approved the study design 
and protocols. All subjects gave fully informed written consent for their inclusion 
within the study. 
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2.1.2   Recruitment 
Initially subjects were recruited from diabetes clinics at Glasgow Royal Infirmary. It 
became apparent that patients attending secondary care diabetes clinics did not fit 
the inclusion criteria for this study. Therefore, subsequent recruitment was via 
advertisements in local press. The process of recruitment and randomisation is 
outlined in Figure 2.1. A total of four adverts were run over an 18-month period in 
two local newspapers (“The Metro”, “The Evening Times”). One-hundred and thirty 
two people responded to these advertisements. Eighty potential volunteers were 
excluded on the basis of a follow-up telephone call. These exclusions were mainly 
due to cigarette smoking, age, being insulin-treated, or having a past history of 
vascular disease. A further 30 were excluded following a health-screening visit. 
Nineteen of these volunteers were excluded on the basis of poor glycaemic control 
(HbA1c >9.0%), seven on the basis of hypertension, and four volunteers were lost to 
follow-up at this stage. 
 
22 male and female patients (subjects) were recruited for this study. All subjects had 
type 2 diabetes diagnosed more than three months earlier. Subjects were treated 
with diet therapy or metformin. Subjects were recruited if they were obese (BMI 
>30kg/m2). Within the intervention group, six subjects were taking no glucose-
lowering medication, seven subjects were prescribed metformin and three were 
prescribeda sulphonylurea. Nine of the fifteen subjects within the intervention group 
were had been prescribed cholesterol lowering drugs No medication was 
discontinued or altered during the study. Subjects had no history of cardiovascular 
disease or microvascular complications related to diabetes. 
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Exclusion criteria included: 
  Cigarette smoking 
   Hb A1c > 9.0% 
  Total serum cholesterol > 8.0mmol/l   
  Insulin therapy 
  History of microvascular or macrovascular complications 
  History of delayed wound healing 
  Pregnancy or breast-feeding 
  Blood pressure >160/90  
 
At screening, volunteers completed confidential health history questionnaires, had 
their weight and height measured, had their blood pressure checked and had 
screening blood samples taken in the fasting state to check for inclusion / exclusion 
criteria. 
 
 
2.1.3 Randomisation 
Subjects were randomised to a six-week period of low calorie diet or usual care 
using a permuted block randomisation technique, with block sizes of 6 and an 
allocation basis of 2:1. This was combined with stratified randomisation to ensure 
equal numbers of subjects with controlled hypertension in each group. 
Randomisation was performed by Dr L Murray, Biostatistician, Department of 
Medicine, Western Infirmary, Glasgow.  Fifteen subjects were randomised to low 
calorie diet and seven were randomised to usual care.  
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2.2 Study protocol 
On each attendance subjects attended fasting having been instructed to avoid food 
or fluids other than water for at least 12 hours prior to the study. All examinations 
and investigations were performed in the morning.  An attempt was made to start 
each session between 0830 and 0900. 
 
In order to reduce anxiety and delay, all subjects were offered transport to and from 
the CIRU and their home address.  A light lunch was provided following each 
investigation session. 
 
All subjects were issued with contact details for the principle investigator and advised 
that contact could be made at any time if required. 
 
Subjects attended for three visits in a week to have initial tests performed. Thereafter 
all subjects had an introductory one-hour session with the dietician, for baseline 
measurements and to discuss dietary issues specific to their randomisation.  
Subjects who were randomised to the low calorie diet group visited the dietician once 
weekly for the next six weeks; subjects randomised to the usual care group visited 
the dietician on one occasion at the start of the six week period and once at the end. 
 
All subjects had a one-week dietary washout after the six-week diet period. Another 
three visits then took place in order that anthropometric, metabolic and vascular 
measurements could be repeated. This protocol is illustrated in Figure 2.2. 
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Figure 2.1: Recruitment and randomisation process 
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Figure 2.2: Study design  
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2.3 Dietary intervention 
2.3.1 Intervention subjects 
A dietician specialising in diabetes management reviewed subjects who were 
randomised to the low calorie diet on a weekly basis for six weeks. The purpose of 
these visits was to encourage dietary compliance and perform basic anthropometric 
measurements. All dietary assessments and anthropometric measurements were 
carried out by the same trained observer. 
 
Dietary composition was based mainly on liquid foodstuffs such as cereals, soups, 
yoghurts, milky puddings and fruits. Calorie intake was restricted to 1200kcal/day. 
Some “solid” foodstuffs were introduced after four weeks in several patients. Patients 
were supplied with booklets containing detailed information on calorie content of a 
number of foodstuffs and were asked to keep accurate daily food and calorie intake 
diaries. 
 
Following six weeks of low calorie diet, subjects were advised to adhere to a calorie 
intake of 2000kcal/day for weight maintenance purposes.for one week, prior to 
repeat vascular and metabolic assessments.    
 
No advice was given to subjects regarding exercise at any point during the study. 
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2.3.2  Control subjects 
The dietician saw these subjects on two occasions: once at the start of the six-week 
period and once at the end. Basic anthropometric measurements and a “diet history” 
were taken. These subjects were given advice about healthy eating, but were not 
given specific instructions about a low calorie diet.  
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2.4. Clinical and morphometric measurements 
2.4.1 History and Examination 
A standard clinical history was taken and clinical examination made.  Particular 
attention was made to symptoms and signs of cardiovascular disease.  A record was 
made of history and examination findings, and of any regular medication taken.  In 
the case of subjects recruited from diabetic clinic, the subject‟s general practitioner 
(GP) was informed of their inclusion in the study, along with details of the 
investigations involved. 
 
 
2.4.2  Blood pressure 
A standard technique was employed throughout the course of the study.  Supine 
systolic and diastolic blood pressure were recorded after a standardised 15 minutes 
rest by an oscillometric technique using an semi-automatic sphygmomanometer 
(Dinamap Critikon, Johnson and Johnson Professional Products Ltd., U.K.) 
maintained by the Department of Clinical Physics, Western Infirmary. 
 
 
2.4.3  Body Mass Index 
A standard technique was employed throughout the course of the study.  A single 
trained observer made measurements.  Height and weight were measured without 
shoes and in indoor clothes.  The same measuring scales were used throughout 
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(Seca, Germany).  Height was measured, as far as was possible, to the nearest 
0.005m.  Weight was measured to the nearest 0.5kg. 
 
Body mass index (BMI kg/ m2) was calculated according to the following standard 
equation: 
BMI = (body weight [kg]) / (height [m2]) 
 
 
2.4.4  Waist-hip ratio 
A standard technique was employed throughout the course of the study.  A single 
trained observer made measurements.  Waist circumference was taken as the 
minimum value between iliac crests and costal margin, with hip circumference taken 
as the maximum value over the buttocks.  A 1cm wide tape measure was used. 
 
 
2.4.5 Skinfold thickness measurements 
These measurements were performed using Hotain Tanner/Whitehouse Skinfold 
callipers (Holtain Ltd., Crymych, UK). Skinfold thickness was measured at the 
following sites on the right side of the body with subject standing: 
 
Biceps: With the elbow flexed at an angle of 90o, the mid point between the lateral 
projection of the acromial process and the inferior margin of the olecranon process 
was marked. The arm was allowed to hang loosely with the palm facing forward and 
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skinfold measurement was made at the level of the mark over the belly of the biceps 
muscle above the centre of the cubital fossa. 
 
Triceps: This measurement was at the same level as the biceps measurement on 
the midline of the posterior aspect of the arm.  
 
Subscapular: This measurement was made along the natural cleavage line of the 
skin just inferior to the inferior angle of the scapula with subjects‟ arms hanging 
loosely by the sides of the body.  
 
Suprailiac: This skinfold was measured vertically in the mid-axillary line, half way 
between the costal margin and the superior iliac crest. 
 
Each skinfold was lifted between the thumb and index finger of the investigator‟s 
right hand, 1 cm above the site of measurement. Skinfold callipers were applied and 
the measurement taken after 5-8 second of calliper pressure.  
 
The sum of skinfold measurements was used to estimate body density using the 
predictive equations derived by Durnin and Womersley (1974): 
  
d = 1,1714 - 0.063 * log (S) - 0.000406*A 
 
Where d is body density, S is sum of all four skinfolds, and A is age in years. 
 
Body fat percentage was then estimated using the Siri equation: 
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%BF = [(4.95/BD)-4.5] x 100 
Where BD is body density. 
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2.5 Body Composition measurements 
2.5.1 Air displacement plethysmography 
The air-displacement plethysmograph used in this study was the BOD POD body-
composition system (model 2000A; Life Measurement Instruments, Concord, CA). 
The device consists of a computer-integrated, dual chambered air-plethysmograph, 
digital weighing scale and BOD POD software system. The system is located in the 
University Department of Human Nutrition at Glasgow Royal Infirmary (Figure 2.3). 
Measurements were carried out in a temperature–controlled room. The BOD POD 
device was initially calibrated using a 50-litre cylinder prior to each measurement. 
 
For measurements, subjects were asked to change into a tight-fitting swimming 
costume and swimming cap, and were asked to remove all jewellery. Subjects‟ 
height, sex and age were entered into the computer. Body weight was then 
measured on a calibrated electronic scale. Subjects were asked to sit quietly with an 
erect posture and normal respiration, with their hands folded in their laps and their 
feet firmly on the floor of the device. A minimum of two 50-second tests was 
performed to ensure reliability of the measures. The body volume measurement was 
repeated if the two measurements were not within 150ml of each other. The device 
then estimated the subject‟s thoracic gas volume. 
 
Once measurements were completed, the system‟s computer with the following 
equation calculated body density: 
Db(AP) = mass/Vb(AP) 
where Vb(AP) is body volume determined by air-displacement plethysmography (AP). 
 108 
Percentage body fat by AP (%BFAP) was derived by using Siri‟s formula: 
Siri: %BFAP = (4.95/Db) - 4.50     
 
 
2.5.2 Deuterium dilution technique 
Total body water (TBW) was calculated from the distribution of a dose of deuterium 
oxide (2H2O or sometimes referred to as D2O) in body water.  Urine, saliva or plasma 
can be sampled.   
 
a. Collection of samples and administration of deuterium labelled water 
A pre-dose urine sample was collected and an aliquot transferred to a clearly 
labelled sterile universal container for storage and deuterium analysis.  ~20ml 
samples were stored and the remaining urine was discarded.  A prepared deuterium 
dose, giving 0.05g 2H2O per kg body weight, was taken orally.  Drinking water was 
used to rinse the vessel, which contained the dose and this was swallowed.  The first 
three urine samples passed after taking the dose were collected and stored in 
labelled universal containers.  The total volume and time urine was passed was 
logged. The urine samples were stored in a freezer at -20C until analysis. 
 
b. Analysis of deuterium 
The deuterium contents of urine, diluted dose and tap water samples were 
determined by continuous-flow isotope ratio mass spectrometry (Hydra, PDZ 
Europa) at the University Department of Child Health, Royal Hospital for Sick 
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Children, Glasgow.  Samples were analysed in triplicate after equilibration with a 
reference gas (5% hydrogen in helium) over a platinum catalyst.  The mass 
spectrometer was calibrated using gravimetric standards of known deuterium 
content, which were prepared and analysed with each batch of samples.  Total body 
water was calculated by isotope dilution of the deuterium dose after correction for 
non-aqueous hydrogen exchange and for deuterium passed in the urine.  Lean body 
mass was calculated assuming this is 73.2% water   Body fat is calculated by 
difference: weight minus lean body mass. 
 
c. Calculation of total body water from urine deuterium enrichment 
Enrichment is the abundance of deuterium in a sample above a baseline level and is 
expressed in units of parts per million excess (ppm excess).  A number of equations 
are needed to calculated total body water. 
 
(1) ppm excess D = (ppm D in enriched sample) - (ppm D in the baseline sample)     
Urinary losses (mmol) are calculated from the deuterium content of each sample. 
 
(2) D content (mmol) = (Sample D ppm excess / 106) x (Urine volume (ml) / MW 
H2O) x 1000      
where MW H2O = molecular weight water = 18.0153 
The cumulative loss is the sum of the D content of each sample. 
 
(3) Apparent TBW (mol) in each sample, taking into account non-aqueous H 
exchange, but not urinary losses = 106 / (D ppm excess) x Dose (mmol) / (1000 x 
1.04)    
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where, 
(4) Dose (mmol) = Wt dose consumed (g) / MW D2O x 1000 x Dose D enrichment / 
100   
MW D2O = molecular weight deuterium oxide = 20.0274 
 
(5) Dose D enrichment  = Dose D abundance – D natural abundance   
= 99.9 - 0.015 = 99.885 atom % D    
and 1.04 is the non-aqueous H exchange factor, the proportion of the dose 
sequestered into lipid and protein pools in the body. 
 
(6) TBW (kg or L)  = mol TBW x MW H2O / 1000 
where MW H2O  = 18.0153 
 
True TBW (mol) uses equation with the addition of the cumulative urinary loss.  
 
(7) True TBW (mol) 
    = 106 / (D ppm excess) x (Dose (mmol) – Urinary loss (mmol)) / (1000 x 1.04)    
 
True moles TBW are converted to kg or L TBW as equation (6) 
The mean TBW of all the plateau samples is used to calculate LBM and body fat.  
The first sample is usually not included, except for calculation of urinary loss. 
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2.6 Hyperinsulinaemic isoglycaemic clamp 
2.6.1 Preparation  
Whole body glucose disposal was measured using the gold standard 
hyperinsulinemic isoglycemic clamp, utilising a technique modified from Defrozo et 
al. (1979). This technique has been shown to be accurated and reproducible by 
Morris et al (1997). 
 
Subjects attended for the investigation fasting.  Two 18-guage PTFE intravenous 
cannulae (Venflon; Viggo, Helsinborg, Sweden) were inserted.  The first was 
inserted in a retrograde fashion into a dorsal vein of the non-dominant hand (Figure 
2.4). The second was inserted into an antecubital vein of the contralateral arm.  A 
three-way tap was attached to each cannula, to allow co-infusion of insulin and 
glucose from the cannula sited in the antecubital fossa, and for ease of blood 
sampling from the retrograde cannula.  Patency of the retrograde cannula was 
maintained by the use of a slow infusion of 0.9% saline. 
 
 
2.6.2  Insulin Infusion 
The infusion of soluble insulin (Actrapid; NovoNordisk A/S, Bagsvaerd, Denmark) 
was prepared in 45 mls 0.9% saline and 5 mls (10% vol / vol) of the subject‟s own 
blood.  The saline / blood mixture was used to prevent absorption of the soluble 
insulin to the plastic of the infusion syringe and lines.  The infusion was administered 
using a Braun Perfusor pump (Braun Medical Inc, Carrollton, Texas, USA).  A 
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primed, constant rate infusion was used using a standard priming protocol (table 
2.1), with the aim of achieving a steady-state serum insulin concentration 
approximately 120 U/ml above the fasting level (i.e., a high physiological level). 
 
 
Time Insulin infusion rate 
0-4 minutes 4.5 mU/kg/min 
4-7 minutes 3.0 mU/kg/min 
7-180 minutes 1.5 mU/kg/min 
 
Table 2.1.  Insulin infusion priming protocol 
 
 
2.6.3 Arterialisation of venous blood 
Early experiments using hyperinsulinemic clamps measured glucose in blood drawn 
from the arterial circulation, and adjusted the glucose infusion rate accordingly.  In 
order to avoid the use of arterial cannulation and its attendant risks, „arterialisation‟ of 
the venous circulation in the hand and arm was used.  This was achieved by heating 
the hand cannulated with the retrograde venous cannula in a cylindrical Perspex 
heated box (Department of Physiology and Pharmacology, University of Nottingham, 
Nottingham, U.K.), commencing immediately after cannulation of the dorsal hand 
vein.  Under thermostatic conditions the heater maintains the ambient temperature 
surrounding the hand at 55o C. 
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2.6.4  Glucose infusion and blood sampling 
20 minutes of supine rest were allowed following cannula placement.  Following this 
period of rest, baseline blood samples were withdrawn and blood pressure was 
measured.  Blood pressure was automatically measured every 15 minutes from this 
point, with automated recording of results. 
 
Insulin infusion was commenced at 0 minutes (t = 0 min) as described above.  A 
20% dextrose (Baxter Healthcare, Norfolk, U.K.) infusion was administered via an 
IMED infusion system (IMED, Abingdon, U.K.), commencing at t = 2 min and 
continuing until t = 180 min.  Serum glucose concentrations were maintained at 
fasting plasma glucose levels.  The infusion rate was adjusted according to body 
weight and recorded as milligrams of glucose infused per kg body weight per minute 
(mg/kg/min).  This was calculated as shown, for a 70kg man (20% glucose infusion): 
 
(60 minutes / 200g glucose) x (70kg) = 21ml / hour 
 
Arterialised blood samples were withdrawn at 10-minute intervals throughout the 
clamp.  1 ml samples were withdrawn from the retrograde cannula and spun in a 
centrifuge.  Serum glucose analysis was performed at the bedside.  The rate of 
glucose infusion was adjusted according to the serum glucose concentration to 
maintain target concentration at the level of fasting plasma glucose concentrations. 
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2.6.5  Calculation of insulin sensitivity 
During the period of steady-state serum glucose concentrations (usually taken as the 
last 60 minutes of the clamp), the rate of glucose infusion equals the rate of glucose 
removal from the glucose space (equivalent to glucose metabolised, M).  It is 
assumed the endogenous glucose production is suppressed, thus, the M value is an 
estimate of total body glucose metabolism, and reflects enhancement of tissue 
glucose disposal by insulin. 
 
In practice, the glucose infusion rate must be modified by two factors before it 
approximates M.  The following equation is used to incorporate these two factors: 
 
M = I – UC +SC 
 
where: 
I = glucose infusion rate (mg/kg/min) 
UC = correction for urinary glucose loss [usually negligible during a clamp] 
SC = space correction (mg/kg/min) [for the inevitable deviations from isoglycemia] 
SC, the space correction is calculated as follows (): 
 
SC = (FPG – G) x 17.86 x 0.095 
 
where: 
G = ambient glucose concentration over last 40 min of clamp (mmol/l) 
17.86 = unit conversion factor (mmol/l to mg/dl) 
0.095 = glucose space constant 
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2.6.6 Calculation of MCR 
This was done to take into account changes in fasting plasma glucose before and 
after diet. MCR is calculated from the following equation: 
MCRg (ml/kg/min) = M / FPG x 100. 
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2.7 Analysis of blood samples 
2.7.1 General protocols 
Venous blood samples for laboratory assay were withdrawn at baseline and during 
clamp studies from the retrograde cannula and collected into plain (electrolytes, 
lipids, liver function tests) and sodium citrate (endothelial markers and CRP) tubes. 
All samples were immediately placed in crushed ice prior to centrifugation (3000rpm, 
4C), decanting and storage at –20C. 
 
 
2.7.2 Routine biochemistry 
Routine biochemical analyses were performed on an Olympus AU5200 
autoanalyser. 
 
 
2.7.3 Lipids and CRP 
Total cholesterol, triglyceride, HDL-c and sensitive CRP assays were performed by 
the staff of the Routine Lipids Section (Miss C Gourlay), Biochemistry Department of 
Glasgow Royal Infirmary, using a Hitachi 917 analyser 
 
VLDL and LDL Cholesterol results were calculated using the FRIEDWALD 
EQUATION  
LDL cholesterol (mmol/l) = total Cholesterol-(HDL Cholesterol+Triglyceride/2.19) 
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VLDL Cholesterol (mmol/l)=total cholesterol-LDL Cholesterol – HDL Cholesterol. 
 
 
2.7.4 Endothelial markers 
Dr Lynne Cherry and Miss Pauline Watt of the Metabolic Medicine Group, of the 
Department of Vascular Biochemistry, Glasgow University, carried out ICAM, IL-6 
and Adiponectin analysis. A Multiskan Ascent Plate reader and Ascent Software 
were used for calculation of results. 
 
 
2.7.5 Serum and plasma glucose concentrations 
Serum glucose was measured at 10-minute intervals at the bedside by the glucose 
oxidase method during the clamp studies. A Beckman 2 glucose analyser (Beckman 
Instruments, Fullerton, CA, USA; inter-assay coefficient of variation of 2%) was used 
for this purpose. Results were expressed in mmol/l. The machine was then 
calibrated prior to each study and then re-calibrated hourly with a control solution 
with a glucose concentration of 8.3mmol/l. 
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2.8 Wire Myography  
Wire myography is an in vitro technique that is used to study the function of vascular 
smooth muscle. It is a technique pioneered by Mulvaney and Aalkjaer (1990) 
whereby the properties of small resistance arteries (<500um) can be investigated. 
 
 
2.8.1 Tissue acquisition - Human gluteal fat biopsy 
The subject was positioned prone, and the upper outer quadrant of the buttock was 
exposed.  An aseptic technique was used.  The area identified for biopsy was 
sterilised with iodine-based solution (Betadine; Perdue Pharma LP, Stamford, 
Connecticut, USA).  The area was anaesthetised with lidocaine 1% to a depth of 
approximately 2cm.  An elliptical incision was made and a segment of tissue 
approximately 2.5cm in length, 1cm in width and 1cm in depth was removed.  
Subcutaneous tissue was sutured with 2 deep sutures to adipose and 3 – 5 
interrupted sutures to skin.  A dry dressing was applied.  Subjects returned at 7 days 
for wound inspection and suture removal. 
 
The dissected biopsy was placed immediately in cold (4o C) 0.9% saline for transport 
to the myography laboratory and further dissection. 
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2.8.2  Preparation and dissection of human biopsies 
Gluteal biopsies were transported to the laboratory in 0.9% saline, as above.  On 
arrival in the laboratory, they were transferred to cold physiological salt solution 
(PSS). 
 
Biopsies were transferred from PSS to an agar-filled Petri dish.  Dissection of the 
biopsy was undertaken using a stereoscopic dissecting microscope.  Dissection 
proceeded from the adipose tissue surface of the biopsy, towards the dermal 
surface.  Arteries were localised and were removed from the biopsy and placed into 
cold PSS, before being further dissected to remove adherent adipose and 
connective tissue. 
 
Once dissected, vessels were divided into segments approximately 2mm in length, 
and were stored in cold PSS at 4oC overnight prior to experimentation. 
 
 
2.8.3 Mounting of resistance arteries 
One stainless steel wire (40um diameter) was attached at one end to a jaw of the 
Mulvany-Halpern four-channel myograph (Danish Myo Technologies) by means of a 
screw fitting.  This jaw is attached to a sensitive strain gauge.  One 2mm segment of 
resistance artery was threaded onto this wire and the free end of the wire was 
secured (Figure 2.4).  A second 40m stainless steel wire was passed into the lumen 
of the artery and secured at both ends to the second jaw of the myograph which, in 
turn, was attached to a micrometer (Figure 2.5).  The jaws of the myograph were 
placed in near approximation (Figures 2.6, 2.7).  This arrangement of jaws and 
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transducer allows the radial forces generated by the vessel in constriction and 
relaxation to be measured as it is held between the wires (Figure 2.8). 
 
The 5ml myograph chamber was then filled with PSS and the unit containing the 
bath and jaws placed upon the heated block of the myograph (37oC).  A 5% CO2 / 
95% O2 mixture was bubbled though the PSS in the chamber. 
 
Data acquisition was performed using a Dell Latitude notebook PC2.7.5 interfacing 
with the myograph via an RS232 port.  Powerlab data recording software (DMT) was 
used to record and analyse myographic data obtained. 
 
 
2.8.4  Normalisation 
After a rest period of 45 minutes, each artery was stretched at 1-minute intervals to 
determine the passive exponential wall tension / internal circumference (L) 
relationship.  According to the Laplace equation (P=T/r, where P is effective 
pressure, T is wall tension, and r is internal radius), the equivalent circumference 
(L100) for a transmural pressure of 100 mm Hg was calculated for each vessel with 
an iterative computer method.  Each vessel was then set to the normalized internal 
diameter, L1=0.9xL100/, at which contraction is thought to be optimum.  After 
normalization, the vessels were left for an additional hour and then exposed to a high 
concentration (123 mmol/L) of potassium (KPSS) for a series of 5-minute periods 
until repeatable maximal contractions were achieved. 
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2.8.5  Incubation 
If incubations were required, the substance would be added to the myography 
chamber after vessels had returned to a baseline tension following any previous 
contraction.  All substances were incubated for a period of 30 minutes prior to curve 
generation. 
 
 
2.8.6  Vasodilator protocols 
Vessels were preconstricted with norepinephrine at a concentration of 3x10-7M.  
Following addition of the constrictor, a plateau of response was awaited before 
agonist added.  In order to produce vasodilatation, logarithmically increasing 
concentrations of agonist were added.  In each case, a minimum of 2 minutes was 
allowed between additions of further concentrations of agonist.  If a vasodilator 
response was noted, further agonist was not added until no further dilation was 
occurring (i.e. a plateau phase had been achieved). 
 
 
2.8.7  Vasoconstrictor protocols 
Following incubation if required, logarithmically increasing concentrations of 
vasoconstrictor were added.  After each concentration addition, the plateau phase of 
response was awaited before further constrictor added.  Additions were continued 
until no further increase in tone was noted after two consecutive concentrations, or 
until the greatest concentration available had been added. 
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2.9 Laser Doppler Iontophoresis 
2.9.1 Laser Doppler Imaging 
Measurements of peripheral cutaneous microvascular function were performed non-
invasively using laser Doppler imaging (LDI) combine with iontophoresis of the 
vasoactive substances acetylcholine (ACh, endothelium dependent) and sodium 
nitroprusside (SNP, endothelium independent). The method was discussed and 
validated previously (Ramsay et al. 2002; Ferrell et al. 2002) Measurements were 
conducted in a quiet temperature controlled room, with subjects allowed to 
acclimatize for 30 minutes (Figure 2.10).  
 
 
2.9.2 Iontophoresis 
A battery-powered constant-current iontophoresis controller (MIC-1e; Moor 
Instruments Ltd., Axminster, U.K) was used to deliver the vasoactive drugs. The 
chambers used for iontophoresis (ION 6; Moor Instruments Ltd.) were made of 
Perspex (internal diameter, 22 mm; area, 3.8 cm2) with an internal platinum wire 
electrode.  Doubled-sided adhesive disks were used to attach the chambers to the 
skin of the volar aspect of the forearm, avoiding scratches, hair, broken skin, and 
superficial veins. The chambers were connected to the anode and cathode 
connections on the iontophoresis controller. Voltage across the chambers was 
monitored using a voltage-sensing device (MIC-OP, Moor Instruments Ltd). Because 
a constant current source was used, resistance values were calculated from the 
recorded voltages using Ohm's Law. 
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Control of current delivery was programmed into the software for the laser Doppler 
imager such that current was switched on at the beginning of a scan and remained 
on throughout the scan until the start of the following scan. The current was then 
either left on for the next scan or was switched off once the total charge had been 
delivered.  Current duration was determined by the time taken to complete each 
scan (50s) multiplied by the total number of scans programmed.  To limit the 
iontophoresis dose, resulting from relatively long scan times, low currents were used: 
the protocol involved incremental current delivery with four scans at 5 µA, four at 10 
µA, four at 15 µA, and two at 20 µA, giving a total charge of 8 mC.  Each frame is 
associated with the current delivery during that scan, although the resulting vascular 
response could be delayed owing to the time required for chemical factors to initiate 
it. A 2.5-ml volume of 1% acetylcholine chloride (Sigma Chemical Co., St. Louis, MO, 
U.S.A.) was introduced into the anodal chamber with 2.5 ml of 1% sodium 
nitroprusside (Sigma) into the cathodal chamber. Thus both agents were delivered 
simultaneously during each period of current administration. Fluid was prevented 
from escaping by placing circular 32-mm cover slips over the chambers. The vehicle 
for these drugs was 0.5% NaCl.  
 
 
2.9.3 Perfusion measurements 
Non-invasive measurement of skin perfusion was performed by means of a laser 
Doppler imager (Moor Instruments Ltd.) equipped with a red laser (wavelength, 633 
nm; power, 1 mW; beam diameter, 1 mm).   The technique is based on the Doppler 
shift imparted by moving blood cells in the underlying tissue to the backscattered 
light. The laser is scanned in a raster fashion over both chambers and through the 
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cover slips. The backscattered light is collected by photo detectors and converted 
into a signal proportional to perfusion in arbitrary perfusion (flux) units (PU) that is 
displayed as a colour-coded image on a monitor. Perfusion measurements were 
obtained using the imager manufacturer's image analysis software by outlining a 
region of interest (ROI) around the internal circumference of the chamber.   
Statistical analysis of the ROI was subsequently performed offline to yield the 
median flux value across approximately 700 measurement points.  Twenty repetitive 
scans were taken, the first being a control (before current administration), followed 
by the incremental current protocol described above (14 scans), and followed by five 
further scans with no current administration. 
 
 
2.9.4 Terminology and units used in laser Doppler iontopheresis 
As the volume of tissue sampled is not known, laser Doppler imaging does not 
permit measurement of blood flow in absolute terms, but rather changes in tissue 
perfusion, measured in arbitrary units called flux or perfusion units (PU). The Moor 
LDI has a wide dynamic range, with perfusion measurable across 0-5000 PU. 
Flux: perfusion in arbitrary units (perfusion units; PU) 
 
AUC: area under the curve  
Corrected AUC: area under the curve in which flux is corrected for skin resistance 
using Ohm`s Law. 
 
Perfusion can be corrected for variations in skin resistance between subjects thereby 
reducing measurement variability (Ramsay et al. 2002), and this is expressed as 
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corrected perfusion units which equals PU times the area under the resistance.time 
integral (PU x M.min) 
Charge is expressed in milli Coulombs (mC). 
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2.10 Measures of arterial compliance 
2.10.1 General details 
Measurements of arterial stiffness were made using a Sphygmocor system (Atcor 
Medical, Sydney, Australia), which uses the principle of applanation tonometry to 
record a peripheral arterial waveform, and applying a generalized transfer function to 
obtain a derived central aortic waveform. Flattening (applanation) of a curved surface 
of a pressure-containing structure under the detecting device allows direct 
measurement of the pressure within.  
 
SphygmoCor utilizes a small pencil sized tonometer (pressure transducer) that is 
placed on the skin over the radial and carotid arteries.  The radial and carotid pulses 
were located by palpation with the optimal position selected as the position that 
yielded the quality signal output.  The tonometer was placed at an angle that was 
perpendicular or directly above the artery with the appropriate pressure applied.   
 
The SphygmoCor PWV was determined by using the intersecting tangent algorithm 
to identify the foot of the waveform using gating to the R-wave of the 
electrocardiogram (ECG) for the two sites.  The tonometer was placed at the same 
point of the arteries during all testing.  Recordings were analysed when a 
reproducible signal was obtained (usually two screens or 10 consecutive beats to 
cover a complete respiratory cycle are needed for subsequent analysis).  
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The SphygmoCor machine comes with two assessment facilities, pulse wave 
analysis (PWA) to calculate augmentation index (AI) and pulse wave velocity (PWV).   
 
 
2.10.2 Pulse wave analysis 
Measurements were carried out in a temperature-controlled room with the subject 
lying prone. ECG leads were attached to both arms and the left leg. The distances 
from the sternal notch to the patient‟s right radial artery and carotid artery were 
measured in mm. These measurements were added to the Sphygmocor database 
along with the patient‟s blood pressure, age, sex, weight and height. 
 
Measurements of augmentation index were made by placing a tonometer over the 
most prominent area of pulsation of the right radial artery. Augmentation is probably 
the most important index derived from PWA.  Because of the relationship between 
HR and AI, the software provides an AI value corrected for a HR of 75 beats/min and 
referred to as heart rate corrected –AI (c-AI). 
 
 
2.10.3 Pulse wave velocity 
Measurements were carried out in a temperature-controlled room with the subject 
lying prone.   
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SphygmoCor 2000 uses the principle of foot-to-foot method for calculating PWV.  
With time delay (transit time) measured between the foot of the pressure waves 
recorded at 2 different points (carotid-femoral) for aortic PWV and (carotid-radial) for 
brachial PWV, ECG gating allows the time lapse between pulse waves at the carotid 
and (radial/femoral) sites to be calculated from sequential rather than simultaneous 
measurements.  PWV is calculated as the superficially measured distance divided by 
the transit time and expressed in metres / second (m/s).  PWV is inversely related to 
the distensibility of the arterial walls. 
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2.11 Statistics 
All statistical analyses were performed using a Minitab version 15 software package. 
Results are expressed as mean and the standard error of the mean (SEM). 
Comparisons of anthropometric measurements and circulating markers were made 
using the Student‟s t test. Correlation data was expressed as a Pearson‟s correlation 
coefficient. Comparisons of pD2 and maximal response values for the myography 
studies were made using the Student‟s t test. LDI mean flux data was compared 
using 2 way ANOVA, and AUC data using Student‟s t test. Augmentation index and 
pulse wave velocity were compared using the Student‟s t test.  
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Figure 2.3: BODBOD equipment for the measurement of body composition. 
 
 
 
a
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Figure 2.4: Retrograde cannulation of a dorsal hand vein. 
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Figure 2.5 Vessel secured with first 40µm stainless steel wire. 
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Figure 2.6 Second wire inserted 
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Figure 2.7: Both jaws of myograph opposed with wires mounted 
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Figure 2.8 Jaws attached to a force transduser and a micrometer 
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Figure 2.9 Measurement of radial force generated by vessel 
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Figure 2.10:  Laser Doppler Imager and iontophoresis set-up 
a   Drug chambers 
b   Laser Doppler Imager 
c   Iontophoresis Controller 
d   Voltage monitor (Sensing Device) 
e    Perfusion images 
f   Thermometer probe 
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CHAPTER 3 
EFFECT OF DIETARY INTERVENTION ON 
ANTHROPOMETRIC VARIABLES 
3.1 Summary 
The effect of dietary manipulation on body weight is well established. Although 
measures of BMI and body weight are useful for screening purposes, measures of 
body composition are necessary to determine the effects of diet on total body fat and 
fat-free mass (FFM). This study employed dietary means aiming for both reductions 
in body weight and in fat mass, with relative preservation of FFM. 
 
Subjects were weighed prior to, and every week throughout the 6-week dietary 
intervention. In addition, skinfold thickness measurements, waist circumference and 
hip circumference were obtained at weekly intervals. Body fat percentage was 
measured at the start of and following the dietary intervention period using two 
methods – air displacement plethysmography, and measurement of total body water 
using the deuterium dilution technique. 
 
The mean reduction in body weight following the intervention was 7.66 ± 0.64kg 
(p<0.001). Mean reductions in waist and hip circumferences were 7.67 ± 1.17 cm 
(p<0.001) and 4.93 ± 0.0554cm (p<0.001) respectively. WHR dropped from 0.96 to 
0.93 (p=0.095). Body fat percentage was also significantly reduced when measured 
by air displacement plethysmography, total body water and when estimated from 
skinfold thickness. 
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In summary, a six-week 1200 kcal/day diet leads to significant weight loss, 
reductions in other anthropometric measurements, and reduced body fat percentage. 
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3.2 Introduction 
There is an increasing prevelance of obesity and type 2 diabetes throughout the 
world, however the relationship between adiposity, insulin resistance and type 2 
diabetes, and cardiovascular disease has not yet been fully elucidated. However, 
there is evidence that weight loss, and in particular reduced body fat is associated 
with improvements in metabolic parameters. The main objective of this study was to 
assess the effect of weight loss on vascular function, but it was important to ensure 
that the imposed dietary measures led to weight loss and changes in body 
composition. 
 
BMI and weight are simple yet important means of assessing the effects of a dietary 
regimen, and patients easily understand changes in these measurements. They are 
probably less useful from the point of view of assessing body composition, which is 
why other simple anthropometric measurements such as waist and hip 
circumference were employed in this study. In addition, changes in waist 
circumference are likely to be more accurate in estimating body fat loss than 
changes in weight or BMI. 
 
In addition to anthropometric measurements, body composition was also measured 
using two modalities – total body water measurement and air displacement 
plethysmography. Both of these techniques have been shown to be reliable and 
reproducible in the measurement of body fat mass in adults (Noreen et al 2006). 
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3.3 Methods  
3.3.1 Subjects 
Twenty-two male and female subjects were recruited and randomised to a six-week 
period of dietary intervention or control, as outlined in section 2.1. Fifteen subjects 
were allocated to the intervention group. Due to poor attendance of the seven control 
subjects, the dataset for this subgroup is very small and is therefore not presented 
here. 
 
Written informed consent was obtained from each subject. The local hospital ethical 
review committee approved the study and study protocols. 
 
 
3.3.2 Study protocol 
Subjects attended for investigations before, during and after the six-week dietary 
intervention period as outlined in section 2.2. 
 
 
3.3.3 Anthropometric measurements 
a. Weight and BMI 
Height and weight measurements were obtained and BMI was calculated as per 
section 2.4.1/2. These measurements were undertaken on a weekly basis 
throughout the intervention period. 
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b. Waist and hip circumference measurements 
Waist and hip measurements were obtained, and WHR calculated as per section 
2.4.3. 
  
c. Skinfold thickness measurements 
These measurements were obtained at baseline and after six weeks of dietary 
intervention as per section 2.4.4. 
 
 
3.3.4 Measures of body composition  
a. Air displacement plethysmography 
Body composition was assessed using the BODPOD system (described in section 
2.5.1) at baseline and after the intervention period.  
 
b. Total body water 
Body composition was also assessed using the three-compartment technique of total 
body water as described in section 2.5.2. 
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3.3.4 Statistics  
Results are expressed as mean and the standard error of the mean (SEM). 
Comparisons were made using the Student‟s t test. Correlation data was expressed 
as a Pearson‟s correlation coefficient.  
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3.4 Results   
3.4.1. Effect on body weight and body mass index 
There was a significant reduction in body weight following the dietary intervention. 
(Mean weight at randomisation 100.01 ± 2.34 kg vs. mean weight at study 
completion (six weeks) weight 92.42 ± 2.14 kg, n=15. p<0.0001 (Figure 3.1)).  
 
There was a significant reduction in BMI following the intervention. (Mean BMI at 
randomisation 35.75 ± 0.86 kg/m2 vs. mean weight at study completion 33.21 ± 0.92 
kg/m2, n=15. p<0.0001 (Figure 3.2)). 
 
 
3.4.2. Effect on waist circumference 
There was a significant reduction in waist circumference following the dietary 
intervention. (Mean waist circumference at randomisation 109.47 ± 2.16 cm vs. 
mean waist circumference at study completion (six weeks) 101.43± 1.72 cm, n=15. 
p<0.0001 (Figure 3.3)) 
 
 
3.4.3 Effect on hip circumference 
There was a significant reduction in hip circumference following the intervention. 
(Mean hip circumference at randomisation 114.23 ± 2.87 cm vs. mean hip 
circumference at study completion (six weeks) 109.3 ± 3.04cm, n=15. p<0.0001 
(Figure 3.4)). 
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3.4.4. Effect on waist-hip ratio 
There was no significant difference in waist-hip ratio following the intervention. 
(Mean waist-hip ratio at randomisation 0.96 ± 0.03 vs. mean waist-hip ratio at study 
completion (six weeks) 0.93 ± 0.02, n=15. p=0.095). 
 
 
3.4.5. Effect on body fat percentage estimated from skinfold thickness 
measurements 
Percentage body fat estimated from skinfold thickness measurements was 
significantly lower following the intervention. (Mean percentage body fat at 
randomisation 33.18 ± 0.82% vs. mean percentage body fat at study completion 
32.17 ± 0.83%. n=15, p<0.05 (Figure 3.5)). 
 
 
3.4.6. Effect on body fat percentage measured by BODPOD 
Percentage body fat measured by air displacement plethysmography (ADP) was 
significantly lower following the intervention. (Mean percentage body fat (as 
measured by ADP) at randomisation 38.83 ± 1.91% vs. mean percentage body fat at 
study completion 32.79 ± 2.62%, n=9. p=0.001 (Figure 3.6)). 
 
 
3.4.7. Effect on body fat percentage measured by total body water. 
Mean body fat percentage as measured by the total body water method was 
significantly lower after the intervention than at baseline. (Mean percentage body fat 
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(as measured by TBW) at randomisation 38.25 ± 2.46% vs. mean percentage body 
fat at study completion 36.04 ± 3.03%, n=5. p<0.05 (Figure 3.7)). 
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3.5 Discussion 
This study has shown that adherence to a 1200kcal/day liquid-based diet leads to 
significant reductions in body weight and BMI in subjects with type 2 diabetes. The 
prescribed diet consisting mainly of soups, cereals, puddings and fruit, led to an 8% 
reduction in body weight. It has been shown that body weight reduction of 5-10% has 
health benefits, and weight loss similar to that seen in our study has been associated 
with reduced mortality (Williamson et al 2000). 
 
Unsurprisingly, weight reduction was associated with reduction in waist 
circumference. Waist circumference correlates closely with body weight and BMI and 
also with abdominal obesity (Balkau et al, 2007). In this study the degree of 
reduction in body weight was highly correlated with the change in waist 
circumference (Figure 3.8). This was encouraging as it suggests benefit conferred by 
weight loss in terms of reduction in abdominal obesity. Unfortunately, we did not 
employ another modality for the measurement of abdominal obesity and if the study 
was to be repeated then it may be useful to utilise CT or MRI scanning in order to 
properly assess changes in abdominal and visceral obesity.  
 
More surprisingly perhaps was the highly significant reduction in hip circumference 
associated with weight reduction. In contrast to waist circumference, hip 
circumference has been shown to correlate negatively with the metabolic syndrome 
and type 2 diabetes (Lissner et al, 2001). However, significant reductions in hip 
circumference were demonstrated in a study examining the effects of weight loss in 
a cohort of females with PCOS, using dietary manipulation that was similar to the 
approach adopted in this study (Croisignani et al, 2003). 
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In this cohort, no significant reduction in waist-hip ratio was observed after the 
dietary intervention. Other weight loss intervention studies have observed 
contrasting results in terms of the effect of calorie reduction on WHR. Bergholm et al 
(2003) observed a significant reduction in WHR in combination with mean weight 
loss of 7.3kg in a cohort of females with previous gestational diabetes, following 3-6 
months of diet and orlistat or placebo. In contrast however, weight loss of around 3kg 
following six months treatment with sibutramine in a cohort of patients with type 2 
diabetes was not associated with any change in WHR (Hung et al, 2005). In addition, 
Janssen et al (2002) assigned 38 obese females to diet alone or diet with aerobic or 
resistance exercise for a period of 14 weeks. This was associated with weight loss of 
around 10kg (10% of body weight) in all three groups but no changes in WHR. 
 
There were significant reductions in body fat percentage in this study, as measured 
by three modalities. Mean body fat percentage was lower after the intervention when 
measured by the techniques of air displacement plethysmography, total body 
assessment and estimations derived from skinfold thickness. All three of these 
techniques are reliable and reproducible. However, none of these methods take into 
account the heterogeneous nature of fat-free mass i.e. the variable degrees of bone 
mineralisation and hydration, and this incurs a degree of error in estimating fat-free 
mass. This is a further limitation of this study that could have been overcome by 
measuring body fat percentage with a four-compartment model method such as 
DXA. 
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In addition, there was no correlation between the reductions in body fat percentage 
as measured by three methods in this study. This is likely due to small sample size 
and missing data. 
 
Therefore, this study has demonstrated that significant reductions in body weight, 
waist and hip circumference, and body fat percentage can be achieved following a 
relatively short period of dietary intervention.  
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 Pre diet Post diet p value 
Weight (kg) 100.01 (2.34) 92.42(2.14) p<0.0001 
BMI (kg/m) 35.75 (0.86) 33.21 (0.91)  p<0.0001 
Waist 
circumference 
(cm) 
109.47(2.16) 101.43(1.72) p<0.0001 
Hip 
circumference 
(cm) 
114.23(2.87) 109.3(3.04) p<0.0001 
WHR 0.96(0.03) 0.93(0.02) ns 
% Body fat 
(skinfolds) 
33.18 (0.82) 32.17 (0.32) p<0.05 
% Body fat 
(TBW) 
38.25 (2.46) 36.04 (3.03) p<0.05 
% Body fat 
(BODPOD) 
38.18 (1.91) 32.79 (2.62) p<0.05 
 
Table 3.1: Anthropometric variables at baseline and following intervention. 
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Figure 3.1: Body weight at baseline and following dietary intervention.  
n=15, p<0.0001  
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Figure 3.2: BMI at baseline and following intervention 
n=15, p<0.0001 
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Figure 3.3: Waist circumference (cm) at baseline and following dietary 
intervention. 
n=15, p < 0.0001  
* outlier 
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Figure 3.4: Hip circumference at baseline and following dietary intervention 
n=15, p < 0.0001 
* outlier   
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Figure 3.5 Body fat percentage estimated from skinfold thickness at baseline 
and following intervention. 
n=15, p<0.05. 
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Figure 3.6: Body fat percentage as measured by ADP method at baseline and 
following intervention.  
n=9, p=0.001 
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Figure 3.7: Body fat percentage as measured by deuterium dilution method at 
baseline and following intervention. 
n=5, p<0.05  
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Figure 3.8 Correlation between change in body weight and change in waist 
circumference. 
p=0.01, r=0.633 
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CHAPTER 4  
EFFECTS OF DIETARY INTERVENTION ON METABOLIC 
PARAMETERS 
4.1 Summary 
The effect of weight loss on glucose tolerance and insulin sensitivity is established. It 
is clear that IGT and diabetes can be modified by changes in lifestyle. Insulin 
resistance and hyperglycaemia are associated with endothelial dysfunction and 
increases in the concentrations of inflammatory cytokines, both of which may 
contribute to the increased vascular risk seen in association with diabetes. The aim 
of these particular studies was to measure the effect of weight loss on other 
metabolic and vascular parameters in a cohort of subjects with type 2 diabetes, and 
to assess whether the anticipated improvement in metabolic markers was also 
associated with an improvement in circulating markers of endothelial function and 
inflammation. 
 
Methods: Subjects attended for investigations before and after the intervention 
period. Baseline samples were obtained prior to the clamp study. Other samples 
were obtained during the clamp. Samples were stored and subsequently analysed 
for a number of metabolic and vascular markers. 
 
Results: There were significant reductions in fasting plasma glucose, HbA1c and 
total cholesterol following the intervention. Serum ICAM concentration was reduced 
following the intervention. There were no significant changes in other vascular 
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markers. Significant improvements in AST, ALT and GGT were observed following 
the intervention. Changes in liver function and lipids correlated with changes in 
parameters of glucose tolerance. 
 
Conclusion: Intentional weight loss in obese subjects with type 2 diabetes leads to 
improvements in glycaemic control, cholesterol and liver function. No significant 
changes in inflammatory cytokines were observed.  
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4.2 Introduction 
The prevalence of obesity is increasing in both the developed and developing worlds 
and is threatening to be a major burden on health care resources. The main reason 
for this is essentially the metabolic perturbations associated with increased body 
weight, especially with regards to central abdominal obesity. The association 
between central obesity and insulin resistance is driving the current pandemic of type 
2 diabetes (Gregg et al, 2004). Associated with this is a constellation of other 
biological changes such as hypertension and deranged lipoprotein metabolism, 
collectively known as the metabolic syndrome (Alberti et al, 1998). This combination 
of risk factors promotes a pro-atherogenic environment within the vasculature, and 
ultimately leads to the development of atherosclerotic cardiovascular disease (Gami 
et al, 2007). 
 
Weight loss through means of lifestyle changes, pharmacotherapy and bariatric 
surgery has been shown to improve these metabolic and vascular factors. The 
majority of these studies have been carried out in patient groups without type 2 
diabetes but who do have established risk factors such as insulin resistance and 
hyperlipidemia. In fact, lifestyle interventions have been shown to be very effective in 
reducing the risk or delaying the onset of type 2 diabetes in large randomised 
controlled trials (Tuomilehto et al, 2001; Knowler et al, 2002). The metabolic and 
vascular effects of weight loss are less well documented. Although lifestyle 
interventions in the form of diet and exercise improve insulin sensitivity and 
glycaemic control (Scheen et al, 1998), there is little evidence to suggest that weight 
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reduction is also associated with improvements in circulating markers in patients with 
type 2 diabetes.  
Therefore, a further hypothesis investigated in this study was that weight loss by 
dietary means leads to improvements in circulating metabolic and vascular markers 
in subjects with obesity and type 2 diabetes. 
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4.3 Methods 
4.3.1 Subjects 
Twenty-two male and female subjects were recruited and randomised to a six-week 
period of dietary intervention or control, as outlined in section 2.1. Fifteen subjects 
were allocated to the intervention group. Due to poor attendance of the seven control 
subjects, the dataset for this subgroup is very small and is therefore not presented 
here. 
  
Written informed consent was obtained from each subject. The local hospital ethical 
review committee approved the study and study protocols. 
 
 
4.3.2 Study protocol 
Subjects attended for investigations before, during and after the six-week dietary 
intervention period as outlined in section 2.2. 
 
 
4.3.3 Hyperglycaemic isoglycaemic clamp 
Clamp studies were performed as outlined in section 2.6 
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4.3.4 Analysis of blood samples 
a. General Protocols 
Blood samples were obtained as outlined in section 2.7.1 
b. Routine biochemistry 
Electrolytes and liver function tests were analysed as outlined in section 2.7.2. 
c. Lipids and CRP 
Lipids and CRP analyses were carried out as outlined in section 2.7.3. 
d. Endothelial markers 
Endothelial marker analyses were carried out as outlined in section 2.7.4. 
e. Plasma and serum glucose concentrations 
Plasma glucose concentrations were analysed as outlined in section 2.7.5. 
 
 
4.3.5 Statistics 
Results are expressed and mean ± standard error of the mean (SEM). Comparisons 
were made using the Student‟s t test. Correlation data was expressed as a 
Pearson‟s correlation coefficient. 
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 4.4 Results 
4.4.1 Effect on fasting plasma glucose 
There was a significant reduction in fasting plasma glucose (FPG) concentration 
following the dietary intervention. (Mean FPG at randomisation 9.3 ± 1.92 mmol/l vs 
mean FPG at study completion (six weeks) 7.0 ± 1.26 mmol/l, n=15, p<0.0001 
(Figure 4.1)).  
 
 
4.4.2 Effect on Haemoglobin A1c 
There was a significant reduction in HbA1c concentration following the dietary 
intervention. (Mean HbA1c at randomisation 7.13 ± 0.19% vs mean HbA1c at study 
completion (six weeks) 6.36 ± 0.16%, n=15, p<0.0001 (Figure 4.2)).  
 
 
4.4.3 Effect on serum lipids 
a. Total cholesterol 
There was a significant reduction in serum total cholesterol (TC) concentration 
following the dietary intervention. (Mean TC at randomisation 4.55 ± 0.23 mmol/l vs 
mean TC at study completion (six weeks) 4.18 ± 0.19 mmol/l, n=14, p<0.05 (Figure 
4.3)).  
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b. Low density lipoprotein cholesterol (LDL-c) 
There was no significant difference in calculated LDL-c concentration following the 
dietary intervention. (Mean LDL-c at randomisation 2.53 ± 0.21 mmol/l vs mean LDL-
c at study completion (six weeks) 2.27 ± 0.21mmol/l, n=13, p=0.093).  
 
c. High density lipoprotein cholesterol (HDL-c) 
There was no significant difference in HDL-c concentration following the intervention. 
(Mean HDL-c at randomisation 1.07 ± 0.07mmol/l vs mean HDL-c at study 
completion (six weeks) 1.07 ± 0.05mmol/l, n=13, p=0.90).  
 
d. Very low density lipoprotein cholesterol (VLDL-c) 
There was no significant difference in VLDL-c concentration following the 
intervention. (Mean VLDL-c at randomisation 0.94 ± 0.16 mmol/l vs mean HDL-c at 
study completion (six weeks) 0.88 ± 0.19 mmol/l, n=13, p=0.74).  
 
e. Triglycerides  
There was no significant difference in triglyceride concentration following the 
intervention. (Mean triglyceride concentration at randomisation 2.11 ± 0.32 mmol/l vs 
mean triglyceride concentration at study completion (six weeks) 1.91 ± 0.39 mmol/l, 
n=13, p=0.56). 
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4.4.4 Effect on circulating factors 
a. Adiponectin 
There was no significant difference in serum adioponectin concentration following 
the intervention. (Mean adiponectin concentration at randomisation 2725 ± 379 ng/ml 
vs mean adiponectin concentration at study completion (6 weeks) 3004 ± 359ng/ml, 
n=13, p=0.276). 
 
b. Interleukin-6 (IL-6) 
There was no significant difference in serum interleukin-6 concentration following the 
intervention. (Mean IL-6 concentration at randomisation 3.07 ± 0.45 pg/ml vs mean 
IL-6 concentration at study completion (6 weeks) 4.22 ± 1.03 pg/ml, n=13 p=0.23). 
 
c. Intercellular adhesion molecule 1 (ICAM-1) 
There was a significant reduction in serum ICAM-1 concentration after the 
intervention. (Mean ICAM-1 concentration at randomisation 243.1 ± 11.50ng/ml vs 
mean ICAM-1 concentration at study completion (6 weeks) 226.6 ± 11.70 ng/ml, 
n=13 p=0.002. (Figure 4.4)). 
 
d. High sensitivity c-reactive protein (hsCRP)  
There was no significant change in serum hsCRP concentration following the 
intervention. (Mean hsCRP at randomisation 4.86 ± 1.54 mg/l vs mean hsCRP at 
study completion (6 weeks) 5.40 ± 1.66 mg/l, n=13 p=0.696). 
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4.4.5 Effect on insulin sensitivity 
There was a significant improvement in insulin sensitivity following the intervention. 
(Mean MCR at baseline 6.36 ± 0.97 mg/kg/min vs mean MCR at study completion 
8.83 ± 1.45 mg/kg/min, n=9, p<0.05 (Figure 4.5)). 
 
 
 4.4.6 Effect on Liver Enzymes 
a. Aspartate aminotransferase (AST) 
There was a significant reduction in AST concentrations following the intervention. 
(Mean AST concentration at baseline 32.15 ± 4.57U/l vs mean AST concentration at 
study completion 25.92 ± 3.63U/l n=13. p<0.05 (Figure 4.6). 
 
b. Alanine aminotransferase (ALT) 
There was a significant reduction in ALT concentration following the intervention. 
(Mean ALT concentration at baseline 53.5 ± 12.50 U/l vs mean ALT concentration at 
study completion (6 weeks) 36.4 ± 7.00U/l, n=13, p<0.05, Figure 4.7)).   
 
c. Gamma-glutamyl peptidase (GGT) 
There was a significant reduction in GGT concentration following the intervention. 
(Mean GGT concentration at baseline 49.0 ± 14.70 U/l vs mean GGT concentration 
at study completion 39.7 ± 14.40 U/l. n=13. p< 0.05, Figure 4.8.) 
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4.4.7 Correlations between changes in metabolic parameters before and after 
intervention 
a. IL-6 and hsCRP 
Changes in IL-6 concentrations correlated significantly with changes in hsCRP 
concentrations. 
r=0.89, p<0.0001 (Figure 4.9) 
 
b. LDL-c and FPG 
Changes in LDL cholesterol concentrations correlated significantly with changes in 
FPG concentration  
r=0.56, p<0.05 (Figure 4.10) 
 
c. AST and HbA1c 
Changes in AST concentrations correlated significantly with changes in HbA1c 
levels. 
r=0.74, p=0.004 (Figure 4.11) 
 
d. ALT and HbA1c 
Changes in ALT concentrations correlated significantly with changes in HbA1c 
levels. 
r=0.75, p=0.003 (Figure 4.12) 
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f. ALT and FPG 
Changes in ALT concentrations correlated significantly with changes in FPG 
concentrations. 
r=0.73, p=0.005 (Figure 4.13) 
 
g. ICAM and ALT 
Changes in ICAM concentrations correlated significantly with changes in ALT 
concentrations. 
r=0.57, p<0.05 (Figure 4.14) 
 
h. LDL-c and GGT 
Changes in LDL-c concentrations correlated significantly with changes in GGT 
concentrations. 
r=0.74, p<0.005 (Figure 4.15) 
 
i. Waist circumference and LDL-c 
Changes in waist circumference correlated significantly with changes in LDL-c 
concentrations. 
r=0.67, p<0.02 (Figure 4.16) 
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4.5 Discussion 
4.5.1 Changes in FBP, HbA1c and insulin sensitivity 
This study has demonstrated that lowering body weight by dietary intervention leads 
to significant improvements in fasting plasma glucose and HbA1c. It has been 
recognised for a few decades that marked calorie restriction resulting in weight loss 
can significantly improve glycaemic control in diabetic and non-diabetic subjects 
(Henry at al 1986). A number of other studies have confirmed these findings 
(Goodpaster et al, 1999; Kelley et al, 1993).  
 
The mechanisms underlying improvements in glycaemic control following weight loss 
are unclear. Goodpaster et al (1999) demonstrated that weight loss is associated 
with reduced visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), 
in combination with improved whole body insulin sensitivity. However, while changes 
in total body fat and SAT did not correlate with change in insulin sensitivity, change 
in VAT did (Petersen et al, 2005). The results of this study did not demonstrate 
correlation between changes in glycaemic control parameters and changes in 
measures of body fat and weight, but this may simply be because the study was not 
powered to do so.  
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4.5.2 Liver function tests and association with glycaemic control and insulin 
sensitivity 
We have demonstrated that weight loss leads to reduced serum concentrations of 
liver enzymes in individuals with type 2 diabetes. Mean weight loss of 8% was 
associated with reduced serum concentrations of ALT, AST and GGT. Obesity and 
the metabolic syndrome are associated with fat accumulation in the liver and this can 
lead to a number of clinical scenarios (as outlined in chapter 1). Liver fat is closely 
correlated with serum ALT and AST, and weight loss has been shown to improve 
these parameters in insulin resistant states (Park et al, 1995; Palmer et al, 1990; 
Ueno et al, 1997). 
 
This is the first study to demonstrate significant changes in liver enzymes following 
weight loss induced by diet alone in patients with type 2 diabetes. If these changes 
are indicative of reduced hepatic steatosis in this group of patients, then this adds 
further support for the use of lifestyle intervention in management of type 2 diabetes 
diabetes and the metabolic syndrome. Imaging methods used to assess changes in 
hepatic steatosis such as ultrasound (Engl et al, 2008) and magnetic resonance 
imaging (Cowin et al 2008) were not used in this study. 
 
Here, improvements in liver enzymes were correlated with changes in parameters of 
glycaemic control. Changes in serum concentrations of ALT were closely associated 
with changes in FPG and HbA1c, whilst change in serum AST correlated with 
changes in HbA1c. GGT was correlated with change in FPG. Petersen et al (2005) 
demonstrated that weight loss (of a similar magnitude to this cohort) in a small group 
of patients with type 2 diabetes was associated with significant improvements in 
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hepatic but not peripheral insulin sensitivity. Weight loss of 8% of body weight led to 
normalisation of insulin-induced suppression of hepatic glucose output, with little 
effect on peripheral glucose uptake. These changes were associated with reduction 
in intrahepatic lipid content, but little or no change in intramyocellular lipid content. 
There were no significant changes in liver enzymes in the Petersen cohort, but 
baseline concentrations of ALT and AST were lower than in the current study. A 
further group has also recently shown that ALT is one of the best predictors for the 
development of type 2 diabetes in males (Sattar et al, 2004; Sattar et al 2007), also 
raising the possibility that intrahepatic fat deposition may be one of the main factors 
at play in the development and control of type 2 diabetes.  
 
 
4.5.3 Changes in plasma lipid concentrations 
The changes in plasma lipids observed in this study are not surprising. A significant 
reduction in mean total cholesterol concentration of around 0.38mmol/l, and a 
reduction in mean LDL-c concentration of 0.26mmol/l are fairly typical for weight loss 
of approximately 8% of body weight. A meta-analysis of seventy trials (Dattilo et al, 
1992) has suggested that total cholesterol falls by 0.05mmol/l per kg reduction in 
body weight. In addition, LDL-c and triglyceride concentrations fall by around 
0.02mmol/l and 0.015mmol/l respectively per kg of body weight lost. Surprisingly, 
HDL-c concentrations also fall during the active stage of weight reduction, and this 
only increases during subsequent weight stabilisation. The changes in lipid 
concentrations observed in this study are of a similar magnitude to those noted 
above. 
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In addition, this study has also demonstrated a positive association between change 
in serum LDL-c concentration and change in waist circumference. This is similar to 
results of a study of 110 obese (non-diabetic) women, where falls in LDL-c and total 
cholesterol were closely associated with a reduction in waist circumference, but not 
WHR (Han et al 1997). 
 
 
4.5.4 Changes in circulating markers 
Despite moderate reductions in body weight there were few changes in circulating 
factors after the dietary intervention in this study. With the exception of ICAM, all 
other cytokines were essentially unchanged after the period of weight loss. The 
available evidence on the changes in adipocytokines following weight loss also 
seems to be variable. 
 
 
4.5.5 Significant reduction in serum ICAM-1 
Our results demonstrated a significant reduction in serum ICAM-1 following weight 
reduction. Intracellular adhesion molecules are found on the surface of the 
endothelium and stimulate the adhesion of monocytes to the endothelium, this being 
one of the initial stages in the formation of the atherosclerotic plaque. It has been 
shown that circulating levels of ICAM-1 are elevated in diabetes (Wagner et al, 
1997), suggesting that hyperglycaemia is associated with an increase in the 
adhesive properties of endothelial cells, and it has also been demonstrated that 
levels of circulating ICAM-1 correlates with degree of hyperglycaemia in patients with 
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type 2 diabetes (Bluher et al, 2002). ICAM-1 and other cellular adhesion markers are 
also associated with obesity.  
 
Although it has been demonstrated repeatedly that weight loss is associated with 
reductions in ICAM-1 (Hamdy et al, 2003; Keogh et al, 2008; Sharman et al, 2004) 
there is no evidence that improved glycaemic control leads to significant changes in 
serum concentrations of cellular adhesion markers (Yudkin et al, 2000; Bagg et al, 
2001). However, weight loss and improved glycaemic control often occur 
simultaneously. Pontiroli et al (2004) assessed the individual effects of each of these 
on serum ICAM-1 concentrations. A cohort of morbidly obese patients both with and 
without diabetes was treated with gastric banding surgery or dietary advice. Serum 
ICAM-1 concentrations were associated with hyperglycaemia and increased body 
weight. Although similar reductions in HbA1c were seen in both groups, weight loss 
was only observed in the group that had undergone bariatric surgery. Reductions in 
serum ICAM-1 levels were only seen in this subgroup. 
 
TNF is produced by adipocytes and can stimulate ICAM-1 production from the 
endothelium. This has been postulated as a potential mechanism for the changes 
observed with weight loss. In this study, TNF was not measured and therefore 
correlations between changes in these two circulating markers cannot be made.  
 
 
4.5.6 Lack of changes in other circulating markers 
Results from studies examining the effects of dietary interventions on circulating 
markers in non-diabetic populations seem to suggest that weight loss leads to 
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amelioration in the proinflammatory environment associated with insulin resistance 
(Sharmann et al, 2004; Esposito et al, 2003; Ziccardi et al, 2002). However data from 
cohorts of diabetic subjects is scarce. Only three other small studies have assessed 
the effects of dietary induced weight loss in patients with type 2 diabetes. Barinas-
Mitchell et al (2006) demonstrated significant reductions in IL-6, TNF, CRP, PAI-1 
and fibrinogen in 38 volunteers following average weight loss of around 10%. A one-
year programme of diet, exercise and either orlistat or placebo led to these results. 
These results are obviously contrasting to the present study, but the duration, nature 
and timescale of the intervention was very different from the approach we adopted. 
In contrast, Giannopoulou et al (2005) looked at the effects of diet and exercise on 
40 female patients with type 2 diabetes over a 14-week period. This cohort lost an 
average of 5kg, and although there were reductions in CRP and leptin 
concentrations, serum concentrations of resistin, IL-6 and TNFa remained 
unchanged. Similarly, four weeks of diet and exercise in 20 male volunteers led to 
mean weight reduction of around 4kg and improved glycaemic control (Halle et al, 
1999). These changes were associated with reduced total cholesterol and leptin 
concentrations. However, no other circulating markers were measured.  
 
There are a number of possible reasons why these results did not demonstrate 
significant changes in inflammatory markers despite weight loss. One explanation is 
that weight loss alone (without exercise) is insufficient to achieve significant 
alterations in serum concentration of inflammatory cytokines. Certainly it has been 
demonstrated that exercise is associated with reductions in serum IL-6 (Dekker et al, 
2007) and resistin (Kadoglou et al, 2007) concentrations in subjects with type 2 
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diabetes. However, Giannopoulou et al were unable to demonstrate these findings in 
any of their three subgroups (diet alone, diet and exercise, exercise alone).  
 
A further reason for the lack of change in inflammatory cytokines in this study could 
be the duration of the dietary intervention. Subjects lost an average of 8kg over a 6-
week period, followed by a 1-week period of dietary washout.  Although weight loss 
was of a similar magnitude in the Bariinas-Mitchell study (7.8% body weight), the 
length of time taken to achieve these losses was much longer (approximately one-
year). Calorie reduction in our cohort was obviously more dramatic than in other 
studies. There is evidence that short-term starvation actually increases skeletal 
muscle IMLC and promotes peripheral insulin resistance. Perhaps relative starvation 
/ calorie reduction has a similar effect. Although total body insulin resistance was 
reduced in our study, this could be due to significant reduction in hepatic insulin 
resistance with minimal change or an increase in skeletal muscle insulin resistance. 
One of the limitations of this study is that no assessment of the relative contributions 
of peripheral and hepatic insulin resistance were made. There are no studies that 
assess the effects of starvation on adipocytokine concentrations.  
  
 
4.5.7 Correlation between IL-6 and CRP 
We noted a very strong correlation between the changes in IL-6 and hsCRP 
concentrations. Although neither of these changed significantly after the intervention, 
it was clear the there was a marked association between concentrations of these two 
substances. IL-6 has been shown to up-regulate hepatic production of CRP and 
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correlation between changes in these two substances has been demonstrated 
previously in a weight loss intervention study (Esposito et al, 2003). 
 
 
In summary, weight loss of approximately 8 kg was associated with improvements in 
glycaemic control, insulin sensitivity, total cholesterol and serum concentrations of 
liver enzymes in this cohort of subjects with type 2 diabetes. There was also a 
significant reduction in serum ICAM-1 noted. On the other hand, no changes in 
circulating levels of adiponectin, CRP or IL-6 were observed.  
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 Pre intervention Post intervention p value 
FPG (mmol/l) 9.3 ± 1.92 7.0 ± 1.26  p<0.0001 
HbA1c (%) 7.13 ± 0.18 6.36 ± 0.15 p<0.0001 
TC (mmol/l) 4.55 ± 0.22 4.18 ± 0.18 p<0.05 
LDL-c (mmol/l) 2.53 ± 0.21 2.27 ± 0.21 ns 
HDL-c (mmol/l) 1.07 ± 0.07 1.07 ± 0.05 ns 
VLDL-c 
(mmol/l) 
0.94 ± 0.15  0.88 ± 0.19 ns 
Triglycerides 
(mmol/l) 
2.11 ± 0.32 1.91 ± 0.39 ns 
Adiponectin 
(ng/ml) 
2725 ± 379  3004 ± 359 ns 
IL-6 (pg/ml) 3.07 ± 0.45 4.22 ± 1.03 ns 
ICAM (ng/ml) 243.1 ± 11.50  226.6 ± 11.70 p=0.002 
HSCRP (mg/l) 4.86 ±1.54 5.40 ± 1.66 ns 
AST (IU/l) 32.15 ± 4.57 25.92 ± 3.63 p<0.05 
ALT (IU/l) 53.5 ± 12.50 36.4 ± 7.00 p<0.05 
GGT (IU/l) 49.0 ± 14.70 39.7 ± 14.40 p< 0.05 
 
Table 4.1: Metabolic and vascular parameters at baseline and following dietary 
intervention. 
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Figure 4.1 Fasting plasma glucose concentration before and after dietary 
intervention. 
p< 0.0001, n=15 
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Figure 4.2: Serum (Haemoglobin A1c) HbA1c concentration before and after dietary 
intervention.  
p<0.0001, n=15 
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Figure 4.3: Serum total cholesterol concentration at baseline and following 
intervention. 
p<0.05, n=13 
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Figure 4.4 Serum intracellular adhesion molecule 1 (ICAM-1) concentration at 
baseline and following dietary intervention. 
n=13. p=0.002 
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Figure 4.5: Metabolic clearance rate (MCR) of glucose at baseline and following 
dietary intervention. 
n=9, p<0.05 
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Figure 4.6 Serum aspartame transferase (AST) concentration at baseline and 
following dietary intervention. 
n=13. p<0.05 
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Figure 4.7 Serum alanine transferase (ALT) concentration at baseline and following 
dietary intervention. 
n=13. p<0.05 
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Figure 4.8 Serum gamma-glutamyl transferase (GGT) concentration at baseline and 
following dietary intervention. 
n=13. p<0.05 
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Figure 4.9: Relationship between change in interleukin-6 (IL-6) and c-reactive 
protein (CRP) concentrations following dietary intervention. 
r=0.89, p<0.0001 
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Figure 4.10: Relationship between change in fasting plasma glucose (FPG) and low 
density lipoprotein cholesterol (LDL-c) concentration following dietary  intervention. 
r=0.56, p<0.05 
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Figure 4.11: Relationship between change in serum aspartame transferase (AST) 
and haemoglobin A1c (HbA1c) concentration following dietary intervention. 
r=0.743, p=0.004
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Figure 4.12: Relationship between change in alanine transferase (ALT) and 
haemoglobin A1c (HbA1c) concentrations following intervention. 
r=0.751, p=0.003 
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Figure 4.13: Relationship between change in fasting plasma glucose (FPG) and 
alanine transferase (ALT) concentrations following intervention. 
r=0.729, p=0.005 
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Figure 4.14: Relationship between change in intracellular adhesion molecule-1  
(ICAM) and alanine transferase (ALT) concentrations following intervention. 
r=0.57, p<0.05 
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Figure 4.15: Relationship between change in serum low density lipoprotein 
cholesterol (LDL-c) and gamma-glutamyl transferase (GGT) concentrations following 
intervention. 
r=0.742, p<0.005 
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Figure 4.16: Relationship between change in waist circumference and serum  
low density lipoprotein cholesterol (LDL-c) concentration following intervention . 
R=0.674, p<0.02 
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CHAPTER 5 
EFFECT OF DIETARY INTERVENTION ON VASCULAR 
PARAMETERS 
5.1 Summary 
Introduction: Obesity has significant effects on morbidity and mortality, especially 
from cardiovascular causes. Associations between obesity, diabetes and endothelial 
dysfunction are established. The exact effect of weight loss on vascular function is 
unclear, with results conflicting. This is especially true in the case of type 2 diabetes 
where there is a lack of published evidence.  
Methods: Each subject underwent vascular assessments before and after dietary 
intervention. 
Results: Results from the wire myography studies showed either no change or a 
significant deterioration following weight loss. In addition, laser Doppler studies 
suggested deterioration in endothelium-dependent vasodilatation after the 
intervention. There was no significant change in augmentation index, but a 
significant improvement in pulse wave velocity after dietary-induced weight loss. 
Conclusions: The results of these studies are also conflicting. There would appear to 
be deterioration in small vessel endothelial function following the intervention, with a 
significant improvement in one parameter of arterial stiffness. The reasons for these 
discrepancies are unclear and further studies in this area are warranted.
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5.2 Introduction 
The links between obesity, diabetes and vascular disease have been well 
established. Evidence suggests that diabetes increases the risk of cardiovascular 
mortality by two to six times that of the general population (Haffner et al, 1998), 
whilst obesity also has a significant impact on cardiovascular morbidity and mortality.  
It has been notoriously difficult to ascertain the effects of weight loss on health, with 
significant difficulties undertaking studies and interpreting results. As endothelial 
function is one of the initial stages in the development of cardiovascular disease, and 
it has been shown to coexist with cardiovascular disease, it would seems logical to 
use this surrogate marker to determine whether improvements in cardiovascular risk 
factors are associated with changes in endothelial function. 
 
A number of groups have tested this hypothesis and have confirmed the association 
between weight loss and improved endothelial function. However, the evidence that 
weight loss improves vascular parameters in subjects with type 2 diabetes remains 
scarce. The main aim of this study therefore, was to demonstrate that intentional 
weight loss improves measurements of endothelial function in subjects with type 2 
diabetes. 
.
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5.3 Methods 
5.3.1 Subjects 
Twenty-two male and female subjects were recruited and randomised to a 6-week 
period of dietary intervention or control, as outlined in section 2.1. Fifteen subjects 
were allocated to the intervention group. Due to poor attendance of the seven control 
subjects, the dataset for this subgroup is very small and is therefore not presented 
here. 
 
Written informed consent was obtained from each subject. The local hospital ethical 
review committee approved the study and study protocols. 
 
 
5.3.2 Study protocol 
Subjects attended for investigations before, during and after the six-week dietary 
intervention period as outlined in section 2.2. 
 
5.3.3 Vascular measurements 
i. Wire Myography 
Tissue acquisition, preparation of arteries and vasoconstrictor and vasodilator 
protocols were carried out as described in sections 2.8.1 – 2.8.7. 
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ii. Laser Doppler iontophoresis 
Laser Doppler imaging and iontophoresis were performed as described in section 
2.9.1 – 2.9.3. 
iii. Measures of arterial compliance  
Pulse wave velocity and pulse wave analysis were carried out as described in 
section 2.10.1 – 2.10.2.  
 
5.3.4 Statistical Analysis 
Results are displayed as mean ± SEM. Comparisons of pD2 and maximal response 
values for the myography studies were made using the Student‟s t test. LDI mean 
flux data was compared using 2 way ANOVA, and AUC data using Student‟s t test. 
Augmentation index and pulse wave velocity were compared using the Student‟s t 
test.  
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5.4 RESULTS 
5.4.1 Wire Myography 
i. Effect of insulin on norepinephrine-mediated contraction pre-intervention  
Analysis of maximal responses and pD2 showed no significant difference in 
norepinephrine-mediated vasoconstrictor responses in the presence and absence of 
insulin (10-9M) in vessels at baseline (Figure 5.1). 
 
ii. Effect of insulin on norepinephrine-mediated contraction post-intervention 
Analysis of maximal responses and pD2 showed no significant difference in 
norepinephrine-mediated vasoconstrictor responses in the presence and absence of 
insulin (10-9M) in vessels following the intervention (Figure 5.2). 
  
iii. Comparison of insulin’s effects on norepinephrine-mediated vasoconstriction 
before and after intervention 
There was no significant difference in pD2 values of norepinephrine-mediated 
vasoconstrictor concentration response before and after intervention when curves 
were compared, although there was a trend towards significance. (Mean pD2 pre-
intervention 6.24 ± 0.11 vs. mean pD2 post-intervention 6.73 ± 0.19; n=6 p=0.06) 
 
There was however, a significant difference when maximal contraction of 
norepinephrine-mediated vasoconstrictor response curves were compared. (Mean 
maximal contraction before the intervention 92.5 ± 2.3% vs. mean maximal 
contraction following the intervention 104.16 ± 3.9%; n=6, p<0.05). (Figure 5.3). 
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5.4.2 Laser Doppler Iontophoresis 
There was a significant deterioration in microvascular responses to iontophoresed 
acetylcholine following the intervention.  
(p<0.0001, two-way ANOVA, n=10, Figure 5.4) 
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5.4.3 Measures of arterial compliance 
i. Pulse wave velocity 
There was a significant reduction in pulse wave velocity after the intervention. (Mean 
PWV at baseline 10.00 ± 0.53 m/s vs. mean PWV following the intervention 6.95 ± 
0.450 m/s, n=4, p<0.0001) (Figure 5.6)). 
 
ii. Pulse wave analysis 
There was no change in augmentation index following the intervention. (Mean AI at 
baseline 24.5 ± 6.05% vs. mean AI following intervention 27.17 ± 6.13%, n=6, 
p=0.56) (Figure 5.7)). 
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5.5 Discussion 
This study has demonstrated deterioration in microvascular function following 
dietary-induced weight loss. Results from wire myography and laser Doppler 
iontophoresis studies, both measuring endothelial function in small blood vessels, 
show a reduction in microvascular responsiveness following the intervention. 
Although the numbers in this study are small, making any statistical comparison 
difficult, there is a clear suggestion of poorer endothelial function following diet-
induced weight loss. It is unfortunate that vessel yield from biopsies was insufficient 
to allow any meaningful assessment of acetylcholine-induced vasodilatation in the 
wire myography studies. However, this was demonstrated in the LDI studies.  
 
The results of the studies of arterial stiffness were different again, with a significant 
improvement in pulse wave velocity following the intervention, but no change in 
augmentation index. Unfortunately, due to technical considerations, the numbers 
available for analysis were small, and as a result the significant results may simply 
have been due to statistical error. 
 
To date, the results of weight loss studies in non-diabetic cohorts have been 
variable. Three studies employing solely dietary methods for weight loss examined 
the effects on vascular function. Raitakari et al (2004) looked at the effect of weight 
loss on two parameters of vascular function. This study demonstrated that reducing 
body weight in 67 obese men and women was associated with significant 
improvements in brachial artery flow-mediated dilation (FMD). In contrast, there were 
no observed differences in endothelium-independent function as assessed by 
vascular responses to sublingual GTN spray. Keogh et al (2007) carried out a 
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randomised parallel design of a low- versus a high-carbohydrate diet, observing 
weight loss of approximately 5% in each group. In contrast to the previous group, 
there were no significant changes in flow-mediated dilatation in either group. 
Furthermore, Dengel et al (2006) observed no improvement in brachial artery FMD 
or endothelium-independent dilatation after weight loss. In addition, no significant 
differences in carotid intima media thickness (IMT) were noted after a period of 
weight loss. There was an improvement in brachial artery compliance in this study. 
 
One study has examined the combined effects of diet and exercise on vascular 
function. Hamdy et al (2003) revealed that a 6-month programme of diet and 
exercise resulted in significant improvements in macrovascular endothelial function 
as measured by flow-mediated dilatation in 24 subjects. However, microvascular 
reactivity measured by laser Doppler imaging remained unchanged. 
 
Dietary measures combined with orlistat therapy have been used in two studies to 
assess vascular responses to weight loss. Brook et al (2004) studied the effect of 
dietary-induced weight loss with or without orlistat in 43 otherwise healthy male and 
female subjects. Mean weight reduction of 6.6kg was not associated with 
improvement in brachial artery FMD in either group. Assessment of forearm 
resistance artery endothelial function was measured by quantifying blood flow 
responses to intra-arterial acetylcholine and SNP (endothelium-dependent and 
independent responses respectively) by Bergholm et al (2003). Despite similar 
weight losses in both arms of the study (diet and placebo vs. diet and orlistat), 
significant improvements in forearm blood flow were seen in the subgroup receiving 
orlistat, but not in the placebo-treated subgroup. 
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The majority of studies designed to examine the metabolic and vascular effects of 
weight loss have, until recently, focused on subjects without diabetes. However, over 
the past few years, a number of groups have studied the effects of weight loss in 
patients with type 2 diabetes. Most of these studies have only observed changes in 
metabolic factors and circulating vascular markers (Halle et al, 1999; Monzillo et al, 
2003; Boudou et al; Giannopoulou et al). Two groups have examined vascular 
function in this setting. Barinas-Mitchell et al (2006) observed significant 
improvements in pulse wave velocity in a cohort of 38 volunteers with type 2 
diabetes, following a year long programme of weight loss including either orlistat or 
placebo. Wycherley et al (2008) observed the effects of weight loss with or without 
exercise training in a cohort of subjects with type 2 diabetes. Weight loss was 
associated with improvements in metabolic parameters but no change in vascular 
function measured by flow mediated dilatation. 
 
The reasons for these varying results are unclear. It has to be noted that the 
baseline characteristics of the cohorts were variable. Some of the groups were 
simply obese but otherwise healthy (Brook et al, 2004), whilst some had other 
significant risk factors for CVD such as hypertension or the insulin resistance 
syndrome (Sasaki et al, 2002; Hamdy et al, 2003). This heterogeneity between 
groups suggest that baseline vascular function between cohorts may differ, and thus 
they may have variable responses to the chosen intervention.  
 
It has also been noted that there are few studies where the degree of weight loss 
correlates with the degree of change in vascular function (Brook, 2006), suggesting 
that there are other factors which affect changes in vascular function rather than 
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weight loss per se. Weight loss has been correlated with changes in other traditional 
risk factors for CVD, such as glycaemic control (Raitakari et al, 2003) and LDL-c 
(Bergholm et al, 2006) although these observations are not universal. In addition, as 
per the previous chapter, there were no significant reductions in CRP or IL-6 
following dietary-induced weight loss. Changes in endothelial function following 
dietary intervention may be due to reduction in inflammatory cytokines, although 
such a relationship has not been demonstrated in any weight loss intervention study 
to date. 
 
Nutrient composition of the various dietary prescriptions could also play a role in the 
results. There is evidence that Mediterranean style diets without weight loss can 
improve endothelial function (Esposito et al, 2004; Fuentes et al, 2001), thought to 
be due to increased levels of antioxidants that have been shown to improve 
endothelial function (Plotnick et al, 1997) and fibre, which may have anti-
inflammatory properties (Antoh et al, 1999). The diet prescribed in the current study 
may have been deficient in certain essential nutrients or low in antioxidants, which 
contributed to the lack of improvement in endothelial function.  
 
A further possibility is that the quantity of salt in the prescribed diet was too high. 
Although this has not been formally analysed, salt content of processed food (which 
was a significant component of the diet in the form of “tinned soup”) is known to be 
high. There is a suggestion that salt may have blood pressure-independent adverse 
effects on vasculature. Tzemos et al (1998) demonstrated that oral salt loading in a 
cohort of healthy individuals led to reduced forearm blood flow responses to 
acetylcholine when compared with a control group. Recent in vitro work has 
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suggested that increases in dietary salt can inactivate eNOS, thereby reducing NO 
availability and vasodilatation (Li et al, 2009). 
 
No other group has used the techniques of wire myography or laser Doppler 
iontophoresis in the assessment of small vessel endothelial function following weight 
loss in subjects with type 2 diabetes. However, Hamdy et al (2003) demonstrated the 
effects of a 6-month programme of diet and exercise in an obese cohort, which led to 
significant improvements in macrovascular endothelial function as measured by flow-
mediated dilatation. However, microvascular reactivity measured by laser Doppler 
imaging remained unchanged. These conflicting results mirror those observed in the 
current study. This suggests that conduit vessels may have different properties from 
resistance arteries and microcirculation. 
 
Previous groups have shown correlation between endothelial function in resistance 
arteries and conduit vessels. Park et al (2001) demonstrated an association between 
endothelial dysfunction in the brachial artery using flow-mediated dilatation, and 
resistance arteries using wire myography in a hypertensive cohort. Agewall et al 
(2006) carried out a similar study in a cohort of subjects with established CHD and 
observed similar associations. Pierce et al (2008) carried out a study to assess the 
effects of weight loss in an obese, nondiabetic cohort. Twelve weeks of dietary 
manipulation led to approximately 10% loss of body weight and significant 
improvements in large vessel and small vessel endothelial function, as measured by 
FMD and peak forearm blood flow in response to intra-arterial infusion of 
acetylcholine respectively. However, results from Hamdy et al (2003) do not show 
correlation between large and small blood vessels.  
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Possible reasons for the discrepancy between large and small blood vessel function 
in this study are unclear. Correlation between endothelial function and pulse wave 
velocity has been demonstrated (Nigam et al, 2003; McEniery at al, 2006), but no 
study to date has looked at the relationship between measures of arterial stiffness 
and endothelial function as measured by either wire myography or laser Doppler 
iontophoresis. The comparative effects of exercise intervention on conduit and 
resistance vessels have been assessed and the changes in each of these 
measurements did not correlate (Green et al, 2004). A number of reasons have been 
postulated for the differences in response to exercise interventions between the two 
types of vessel. 
 
There was a clear reduction in vascular insulin sensitivity as assessed by the wire 
myography studies. Surprisingly the vasodilating effect of insulin on norepinephrine-
induced vasoconstriction was less marked following the intervention, suggesting a 
reduction in vascular insulin sensitivity after weight loss. This is contrary to the 
results from isoglycaemic clamp studies, which show increased metabolic sensitivity 
to weight loss following the same intervention. Again, the numbers are too small to 
gain any meaningful correlation data, but the results are obviously conflicting. Some 
studies from our own group have suggested that insulin‟s vascular and metabolic 
actions are coupled in both healthy and hypertensive cohorts, and may share 
underlying molecular pathogenesis (Cleland et al, 1999; Cleland et al 2000). More 
recently this hypothesis has been challenged by Perry et al (2003) who 
demonstrated that glucocorticoid supplementation in healthy individuals led to 
reduced metabolic effects of insulin but no change in vascular insulin sensitivity.    
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In summary therefore, this study has demonstrated impairment in small vessel 
endothelial function following dietary-induced weight loss. Similar results were 
observed using both in vivo and ex vivo techniques. In contrast, pulse wave velocity, 
a method of measuring arterial stiffness, was improved following the intervention. 
The reasons for these surprising results, especially with regards to small vessel 
function are unclear, but are not dissimilar to previous results in cohorts both with 
and without type 2 diabetes. Potential reasons for the deterioration in vascular 
function could be related to the duration of the dietary intervention, or the 
composition of the diet. The discrepancy between the observed metabolic and 
vascular sensitivity to insulin therapy could add further weight to the argument that 
these two main roles of insulin are not coupled as previously thought.  Further larger 
studies are required in order to clarify these issues.  
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Figure 5.1 Effect of insulin on norepinephrine-mediated contraction before 
intervention. 
n=6. 
Comparison of pD2 = ns. Comparison of maximal response = ns. 
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Figure 5.2 Effect of insulin on norepinephrine-mediated contraction following 
intervention. 
n=6. 
Comparison of pD2 = ns. Comparison of maximal response = ns. 
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Figure 5.3 Effect of insulin on norepinephrine-mediated contraction before and 
following intervention. 
n=6. 
Comparison of pD2 = ns. Comparison of maximal response p<0.05. 
 
 
 
 
 
 
 
 
 
Pre vs Post Diet
(n=6)
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
125
pre-diet
post-diet
log [NA], M
%
 c
o
n
tr
o
l 
m
a
x
im
u
m
 213 
 
  
2018161412108642
2.6
2.5
2.4
2.3
2.2
2.1
2.0
1.9
1.8
Time (mins)
L
o
g
 f
lu
x
 u
n
it
s
Pre intervention
Post intervention
 
Figure 5.4 Endothelium-dependent vasodilatation measured by laser Doppler 
iontophoresis of acetylcholine before and after dietary intervention. 
n=10. p<0.0001, two-way ANOVA. 
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Figure 5.5: Pulse wave velocity (m/s) at baseline and following intervention. 
n=4, p<0.0001. 
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Figure 5.6: Augmentation index (%) at baseline and following intervention. 
n=6, p=ns 
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Chapter 6 
Discussion  
6.1 Introduction  
One of the major challenges to health-care systems throughout the world is to 
reduce mortality and morbidity associated with cardiovascular disease, particularly 
coronary artery disease and cerebrovascular disease. These disease processes 
are mediated by progressive atherosclerosis. This pathological process and its 
clinical sequelae are closely associated with a number of physiological parameters 
such as hypertension, insulin resistance and abnormal lipid profiles, and obesity, 
collectively termed the metabolic syndrome. There is good evidence that lowering 
cholesterol (Collins et al, 2003) and improved glycaemic control in type 2 diabetes 
results in reduced mortality from cardiovascular disease (UKPDS Group, 1998). 
However, it has been more difficult to demonstrate that reduced centripetal obesity 
leads to reduced morbidity or mortality from CVD. Although it is clear that weight 
loss can improve glycaemic control in type 2 diabetes, and thus indirectly affect 
CVD, no study has been able to prove that weight loss per se reduces 
cardiovascular risk, although work is ongoing (Ryan et al, 2003).  
 
Endothelial dysfunction is known to be a precursor to atherosclerotic disease, and 
has been shown to be a surrogate marker of this process (Ross et al, 1993). Over 
the past two decades, a number of tools have been developed and validated to 
measure endothelial function. It has been demonstrated repeatedly that endothelial 
dysfunction is a precursor to clinical disease processes, and is associated with 
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poorer prognoses (Heitzer et al, 2001; Neunteufl et al, 2000). It seems reasonable 
therefore that the measurement of endothelial function would be a useful surrogate 
for observing the possible effects of weight loss on vascular disease processes.  
 
As is the case with type 2 diabetes, hypertension, and cardiovascular disease, 
obesity is closely associated with endothelial dysfunction (Steinberg et al, 2006). A 
number of studies have attempted to demonstrate that weight loss is associated 
with improved endothelial function, using a variety of methods. The results of these 
studies have varied, probably as a result of the heterogeneous nature of the study 
cohorts, and the duration and nature of the intervention adopted. In addition, a 
variety of different methods to assess endothelial function have been used as 
described in Table 1.1.  
 
This study attempted to demonstrate that weight loss is beneficial in terms of 
vascular health in a particularly at risk group. Patients with type 2 diabetes are 
generally overweight and insulin resistant, and have a much higher risk of CVD 
mortality than the general population (Haffner et al, 1998). Numerous studies have 
revealed the benefits of a number of interventions such as improved glycaemic 
control (UKPDS Group, 1998) and lipid-lowering therapy (Collins et al, 2003) on 
cardiovascular disease. Although one of the main driving forces behind the 
development of type 2 diabetes is increased body weight, there is little evidence 
that weight reduction has a significant impact on cardiovascular disease. Very few 
of the previous studies looking at the effects of weight loss on vascular function 
have included subjects with type 2 diabetes, despite their significantly higher 
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cardiovascular morbidity and mortality rates. Therefore, the main objective of this 
study was to demonstrate that intentional weight loss was associated with improved 
endothelial function in subjects with type 2 diabetes. 
 
Initially, attempts were made to recruit diabetic patients treated with diet alone, and 
naïve to statin and angiotensin converting enzyme therapies.  It became apparent, 
however after nine months of recruitment from primary and secondary care that 
there were very few patients with type 2 diabetes who were not taking oral 
medication for primary prevention of cardiovascular disease. It was therefore 
necessary to broaden the inclusion criteria to include such patients. In addition, 
given the intensive nature of the study, both in terms of the dietary intervention and 
the invasive nature of the investigations, many potential subjects were unable to 
commit to this. Both of these reasons made recruitment for this study very labour 
intensive and often fruitless. Data collection was also incomplete for many of the 
subjects, usually because of constraints on their time and availability, especially in 
the second phase of investigations following the dietary intervention. This was 
especially true for the control subjects, who were less motivated to attend for follow-
up. 
 
 
6.2 The effects of weight loss on anthropometric measurements 
This study demonstrated that dietary manipulation leads to a reduction in body 
weight. Six weeks of replacing usual diet with a 1200kcal/day liquid based diet led to 
a mean reduction in body weight of 8kg, equivalent to a reduction of 5-10% in body 
weight. In addition, significant reductions in waist circumference and body fat mass 
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suggested that weight loss was mainly due to reduced central fat mass with 
preservation of fat-free mass. Unfortunately methods to assess the degree of change 
in visceral rather than subcutaneous fat, such as CT or MRI scanning were not 
employed.  
 
Using three different methods, significant reductions in body fat percentage were 
observed following weight loss. Despite this however, there was no correlation 
between the changes in body fat obtained from any of the three techniques used, 
namely skinfold thickness measurements, air displacement plethysmography or total 
body water. The main reason for this is due to the relatively small numbers involved. 
 
6.3 Effect of weight loss on metabolic parameters 
Weight loss has a beneficial effect on many metabolic parameters. It was 
unsurprising therefore that weight loss in this study was associated with improved 
glycaemic control both in terms of HbA1c and fasting plasma glucose 
concentrations. In addition there were significant improvements in whole body insulin 
sensitivity as measured by the hyperisulinaemic isoglycaemic clamp technique in this 
cohort. 
 
This intervention also led to significant improvements in liver function tests which are 
markers of hepatic steatosis, a common finding in individuals with the metabolic 
syndrome and type 2 diabetes. Unfortunately no formal measurement of liver fat 
content (such as CT or MRI scanning) was actually made. However, it has been 
shown that plasma levels of liver enzymes especially ALT are suitable surrogate 
markers of liver fat content (Tiikkainen et al, 2003). Interestingly there were 
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significant correlations between changes in liver function and changes in glycaemic 
control. This has supported the hypothesis that hepatic insulin resistance and the 
development of type 2 diabetes is closely related to liver fat accumulation. 
 
 
6.4 Effect of weight loss on circulating markers of inflammation and 
endothelial function 
 The absence of any significant change in serum concentrations of adipocytokines 
and markers of inflammation following weight loss was surprising. Despite a 
significant reduction in sICAM-1, there were no significant changes in serum 
adiponectin, IL-6 or CRP following the intervention. Despite numerous studies 
demonstrating the benefits of weight loss in terms of reduced cytokine levels in non-
diabetic cohorts, only one study has demonstrated such improvements in a diabetic 
cohort (Barinas-Mitchell et al, 2006). That particular trial adopted a year-long multi-
disciplinary approach to weight loss including an exercise intervention, which has 
been demonstrated as being beneficial in reducing inflammatory markers in type 2 
diabetes (Zoppini et al, 2006; Kadoglou et al, 2007; Dekker et al, 2007).  
 
Potential reasons for the lack of change in inflammatory cytokines are numerous, 
including the duration of the intervention, the amount of weight lost, and the 
composition of the prescribed dietary modifications.  
 
 
 221 
6.5 Effect of weight loss on vascular function 
The results of the vascular function studies were also unexpected. There was a 
significant deterioration in endothelium-dependent vasodilatation of the 
microcirculation as measured by laser Doppler iontophoresis of acetylcholine. In 
addition, ex vivo studies in the form of wire myography also demonstrated that 
insulin-mediated vasodilation deteriorated after weight loss. In contrast, however 
there was a significant improvement in pulse wave velocity measurements following 
the intervention.  
 
These findings are similar to those of the few studies available which have examined 
the effects of weight loss on vascular function in both diabetic and non-diabetic 
groups. Raitakari et al (2004) did demonstrate improved endothelial function as 
measured by brachial artery FMD following mean weight loss of 11 kg. In contrast, 
neither Keogh nor Dengel were able to demonstrate improved endothelium-
dependent vasodilation following weight reduction. In addition, Wycherley et al 
(2008) were unable to demonstrate improvements in brachial artery FMD in a 
diabetic cohort despite changes in metabolic parameters following weight loss. 
However, Barinas-Mitchell et al (2006) and Halle et al (1999) demonstrated improved 
pulse wave velocity following weight loss in diabetic cohorts following weight loss 
induced by diet and exercise.  
 
Therefore, it seems clear that weight loss in subjects both with and without diabetes 
leads to significant improvements in metabolic parameters. The effects of weight 
reduction on endothelial function in type 2 diabetes remains unclear and further 
research into this important subject would seem warranted. 
 222 
 6.6 Missed opportunities and future work 
Whilst the number of investigations performed on subjects in this study was already 
high, there were opportunities missed. Undertaking a direct assessment of liver fat 
content would heve been useful and correlation od liver fat loss with changes in 
insulin sensitivity would have been helpful. Other inflammatory cytokines could also 
have been measured. Given the  deterioration in endothelail function which was 
observed thought to be due to relative starvation, it would have been useful to 
retyest subjects after a further 6 weeks to see if these changes reversed although 
thuis would haveentailed a further invasive biopsy. 
 
The exact role of weight loss on the endothelium remains unclear. Although a 
number of studies have tried to address this issue, results are varied. This is 
probably due to variations in the intervention used and in the method of assess ing 
endothelail function, with there being no current accepted gold standard for this 
measurement. There also appears to be degree of heterogeneity in the type of 
obesity that people have with some being more metabolically dangerous than others. 
Until these basic issues are teased out the answer remains unclear. What is clear 
however is that weight loss has undoubtably a beneficial effect on insulin resistance 
and can only be in the logterm good for people with t2 dm.  
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